Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 1184. Отображено 100.
17-05-2012 дата публикации

Double cross-linkage process to enhance post-implantation bioprosthetic tissue durability

Номер: US20120123557A1
Автор: Alain F. Carpentier, Sophie M. Carpentier
Принадлежит: Edwards Lifesciences Corp

Bioprosthetic tissues and methods for making same, comprising fixing bioprosthetic implant tissue by treatment with 0.1 to 10 wt. % glutaraldehyde at elevated temperature, capping said fixed tissue by treatment with a diamine crosslinking agent, and treating said capped tissue with about 0.6 wt. % glutaraldehyde.

Подробнее
Номер записи: 1
28-02-2013 дата публикации

Device and method for replacing mitral valve

Номер: US20130053950A1
Автор: Mark Chau, Son V. Nguyen, Stanton J. Rowe
Принадлежит: Edwards Lifesciences Corp

A prosthetic mitral valve assembly is disclosed. The assembly comprises a radially-expandable stent including a lower portion sized for deployment between leaflets of a native mitral valve and an upper portion having a flared end. The upper portion is sized for deployment within the annulus of the mitral valve and the flared end is configured to extend above the annulus. The stent is formed with a substantially D-shape cross-section for conforming to the native mitral valve. The D-shape cross-section includes a substantially straight portion for extending along an anterior side of the native mitral valve and a substantially curved portion for extending along a posterior side of the native mitral valve. The assembly further includes a valve portion formed of pericardial tissue and mounted within an interior portion of the stent for occluding blood flow in one direction.

Подробнее
Номер записи: 2
27-06-2013 дата публикации

Unitary Endoscopic Vessel Harvesting Devices

Номер: US20130165746A1
Автор: Chin Albert K.
Принадлежит: PAVILION MEDICAL INNOVATIONS, LLC

Unitary surgical devices are disclosed. Such devices may include an elongated body extending between a proximal end and a distal end, and having one or more lumens extending through the elongated body and a tip disposed at the distal end of the elongated body. The harvesting device may further include a first gripping element disposed about the dissection tip and a second gripping element disposed about the dissection tip distally of the first gripping member. The second gripping member may be moveable with respect to the first gripping member for capturing a blood vessel between the first gripping member and the second gripping member. The blood vessel captured between first gripping member and the second gripping member may then be sealed and, subsequently, severed by a cauterizing element disposed between the first gripping member and the second gripping member. 1. An surgical device comprising:an elongated body extending between a proximal end and a distal end, and having one or more lumens extending through the elongated body;a tip disposed at the distal end of the elongated body;a first gripping element disposed about the dissection tip;a second gripping element disposed about the dissection tip distally of the first gripping member, the second gripping member being moveable with respect to the first gripping member between an open position away from the first gripping member to a closed position toward the first gripping member for gripping a blood vessel between the first gripping member and the second gripping member; anda cauterizing element disposed between the first gripping member and the second gripping member such that the blood vessel, when gripped between the first gripping member and the second gripping member, is pressed against the cauterizing element for sealing the blood vessel.2. The device of wherein the cauterizing element is further used to sever the blood vessel.3. The device of further comprising controls disposed near the proximal end of ...

Подробнее
Номер записи: 3
18-07-2013 дата публикации

Prosthetic heart valve including stent structure and tissue leaflets, and related methods

Номер: US20130184812A1
Автор: Bob Allan, Chad Cai, Lise LaChance, Paul Edward Ashworth, Peter Nicholas Braido, Steven D. Kruse
Принадлежит: St Jude Medical LLC

A method of making a prosthetic heart valve may include providing an annular stent having a plurality of annularly spaced commissure portions having tips, covering each of the tips with a first fabric cover, covering the first fabric covers and the remainder of the stent with a second fabric cover, covering the second fabric cover with a first tissue membrane, and covering the outside of the first tissue membrane with a second tissue membrane, the second tissue membrane forming leaflet portions that extend inwardly between the commissure portions.

Подробнее
Номер записи: 4
21-11-2013 дата публикации

Methods of conditioning sheet bioprosthetic tissue

Номер: US20130310929A1
Автор: Bin Tian, Gregory A. Wright, Ivan Jankovic, James Young, Jeffrey S. Cohen, Jeffrey S. Dove, John F. Migliazza, Louis A. Campbell, Ralph Schneider
Принадлежит: Edwards Lifesciences Corp

Methods for the conditioning of bioprosthetic material employ bovine pericardial membrane. A laser directed at the fibrous surface of the membrane and moved relative thereto reduces the thickness of the membrane to a specific uniform thickness and smoothes the surface. The wavelength, power and pulse rate of the laser are selected which will smooth the fibrous surface as well as ablate the surface to the appropriate thickness. Alternatively, a dermatome is used to remove a layer of material from the fibrous surface of the membrane. Thinning may also employ compression. Stepwise compression with cross-linking to stabilize the membrane is used to avoid damaging the membrane through inelastic compression. Rather, the membrane is bound in the elastic compressed state through addition cross-linking. The foregoing several thinning techniques may be employed together to achieve strong thin membranes.

Подробнее
Номер записи: 5
06-03-2014 дата публикации

Process for Devitalizing Soft-Tissue Engineered Medical Implants and Devitalized Soft-Tissue Medical Implants Produced

Номер: US20140065238A1
Автор: JR. Lloyd, Lange Peny, Linthurst-Jones Alyce, Moore Eric, Naif Barry, Wolfinbarger
Принадлежит: LifeNet Health

The invention provides methodologies and apparatus for producing acellular soft-tissue implants, both in small quantities and in commercializable quantities. Such soft-tissue implants include vascular graft substitutes. An acellular graft is produced by subjecting the tissue sample to an induced pressure mediated flow of an extracting solution, followed by inducing a pressure mediated flow of a treating solution, then washing the treated tissue to produce the acellular graft. The acellular grafts produced are uniform and nonimmunogenic. 1. A process for preparing an acellular soft tissue graft for implantation into a mammalian system , comprising:extracting a soft tissue sample with an extracting solution comprising one or more nonionic detergents and one or more endonucleases, to produce extracted tissue;treating said extracted tissue with a treating solution comprising one or more anionic detergents, to produce a treated tissue;washing said treated tissue with a decontaminating solution comprising one or more decontaminating agents to produce said acellular soft tissue graft; andstoring said acellular soft tissue graft in a storage solution comprising one or more decontaminating agents.2. A process for preparing commercializable quantities of acellular soft tissue grafts for implantation into mammalian systems , comprising:obtaining tissue samples from an acceptable donor; extracting said tissue samples with an extracting solution comprising one or more nonionic detergents and one or more endonucleases, to produce extracted tissue;treating said extracted tissue with a treating solution comprising one or more anionic detergents, to produce a treated tissue;washing said treated tissue with a decontaminating solution comprising one or more decontaminating agents; to produce said acellular soft tissue graft; andstoring said acellular soft tissue graft in a storage solution comprising one or more decontaminating agents.3. A process for preparing an acellular soft ...

Подробнее
Номер записи: 6
05-01-2017 дата публикации

REVASCULARIZATION GRAFT MATERIAL

Номер: US20170000928A1
Автор: Nishioka Eri, Onodera Hiroshi
Принадлежит:

Provided is a graft material capable of securing a sufficient space for regenerated tissue in the implantation site, and thereby promoting the regeneration of a blood vessel. Specifically, the present invention provides a revascularization graft material including an outer tube and an inner tube each being formed by knitting twisted yarns of biodegradable single yarns into a hollow tubular structure, wherein there is provided, in the lumen of the outer tube, at least one inner tube having an outer diameter smaller than the lumen diameter of the outer tube. The inner tube functions as a core material for the outer tube, and accordingly the revascularization graft material is excellent in kinking resistance, and the occlusion of the lumen hardly occurs. 1. A revascularization graft material comprising an outer tube and an inner tube each being formed by knitting twisted yarns of biodegradable single yarns into a hollow tubular structure , wherein there is provided , in the lumen of the outer tube , at least one inner tube having an outer diameter smaller than the lumen diameter of the outer tube.2. The graft material according to claim 1 , wherein the graft material is provided claim 1 , in the lumen of the outer tube claim 1 , with a space formed of the lumen internal surface of the outer tube and the external surface of the inner tube.3. The graft material according to claim 1 , wherein to the outer tube and/or the inner tube claim 1 , one or more factors selected from the group consisting of vascular endothelial growth factor (VEGF) claim 1 , platelet-derived growth factor (PDGF) claim 1 , fibroblast growth factor (FGF) and/or hepatocyte growth factor (HGF) are bound.4. The graft material according to claim 3 , wherein one or more factors selected from the group are bound to the outer tube claim 3 , and one or more other factors selected from the group are bound to the inner tube.5. The graft material according to claim 4 , wherein vascular cells and/or cells to ...

Подробнее
Номер записи: 7
03-01-2019 дата публикации

Decellularized soft-tissue grafts

Номер: US20190001022A1
Автор: Alyce Linthurst-Jones, Barry Nolf, Eric Moore, Lloyd Wolfinbarger, Jr., Perry Lange
Принадлежит: LifeNet Health

The invention provides methodologies and apparatus for producing acellular soft-tissue implants, both in small quantities and in commercializable quantities. Such soft-tissue implants include vascular graft substitutes. An acellular graft is produced by subjecting the tissue sample to an induced pressure mediated flow of an extracting solution, followed by inducing a pressure mediated flow of a treating solution, then washing the treated tissue to produce the acellular graft. The acellular grafts produced are uniform and nonimmunogenic. The inventive method allows for the production of multiple decellularized soft tissue implants, where processing time is significantly less than prior art processes and the number of implants produced per day is increased over prior art processes. In clinical use, the decellularized grafts produced exhibit significantly improved in long-term durability and function.

Подробнее
Номер записи: 8
14-01-2016 дата публикации

Soft Tissue Pouch and Methods of Use Thereof

Номер: US20160008514A1
Автор: JONES Alyce Linthurst
Принадлежит: LifeNet Health

The invention relates to a soft tissue pouch and methods of use thereof. 1. A medical product comprising a medical device and a soft tissue pouch encapsulating the medical device.2. The medical product according to claim 1 , wherein the soft tissue is selected from skin claim 1 , dermis claim 1 , pericardium claim 1 , fascia claim 1 , arteries or veins claim 1 , dura mata claim 1 , ammonic membrane claim 1 , bladder claim 1 , small or large intestine.32. The medical product according to any of - claims 1 , wherein the soft tissue is an autograft claims 1 , an allograft claims 1 , or a xenograft.43. The medical product according to any of - claims 1 , wherein the soft tissue is dermis.54. The medical product according to any of - claims 1 , wherein the basement membrane side of the soft tissue is placed outward.65. The medical product according to any of - claims 1 , wherein the medical device is a pacemaker claims 1 , an ICD claims 1 , an insulin pump claims 1 , or an indwelling catheter.7. A method for preparing a soft tissue pouch for implanting a medical device into a patient claims 1 , comprising:(i) obtaining a mammalian soft tissue;(ii) optionally decellularizing and/or devitalizing the soft tissue;(iii) optionally treating the soft tissue with a plasticizer;(iv) suturing, stapling or gluing the soft tissue into a pouch shape configured to encapsulate a medical device;(v) packaging the soft tissue pouch in a packaging material; and(vi) optionally sterilizing the product.8. A method for implanting a medical device into a patient claims 1 , comprising(i) encapsulating the medical device into a soft tissue pouch;(ii) closing the opening of soft tissue pouch; and(iii) implanting the medical device with the soft tissue pouch.9. The method according to or claims 1 , wherein the soft tissue is selected from skin claims 1 , dermis claims 1 , pericardium claims 1 , fascia claims 1 , arteries or veins claims 1 , dura mata claims 1 , ammonic membrane claims 1 , bladder ...

Подробнее
Номер записи: 9
27-01-2022 дата публикации

Extracellular Matrix Tissue Prostheses

Номер: US20220023503A9
Автор: Matheny Robert G
Принадлежит:

Tissue prostheses having a base structure and a physiological sensor system. The tissue prostheses are adapted and configured to induce remodeling of damaged tissue and regeneration of new tissue and concurrently detect and monitor physiological characteristics when implanted in the subject. 1. A tissue prosthesis , comprising:a base structure and a physiological sensor system, said physiological sensor system being joined to said base structure,said base structure comprising an extracellular matrix (ECM) composition comprising acellular ECM from a mammalian tissue source, said base structure, when disposed proximate damaged biological tissue, being adapted to induce modulated healing of said damaged tissue, said modulated healing comprising reducing an inflammatory phase of said damaged tissue and inducing host tissue proliferation, bioremodeling and, thereby, neovascularization of said damaged tissue, and regeneration of new tissue and tissue structures,said base structure and physiological sensor system being jointly adapted to concurrently induce said modulated healing and detect at least one physiological parameter of said subject, when disposed proximate said damaged biological tissue of said subject.2. The tissue prosthesis of claim 1 , wherein said mammalian tissue source comprises mammalian tissue selected from the group consisting of small intestine submucosa (SIS) claim 1 , urinary bladder submucosa (UBS) claim 1 , stomach submucosa (SS) claim 1 , urinary basement membrane (UBM) claim 1 , liver basement membrane (LBM) claim 1 , amniotic membrane claim 1 , mesothelial tissue claim 1 , placental tissue and cardiac tissue.3. The tissue prosthesis of claim 1 , wherein said ECM composition further comprises an additional biologically active agent.4. The tissue prosthesis of claim 3 , wherein said biologically active agent comprises a growth factor selected from the group consisting of a basic fibroblast growth factor (bFGF) claim 3 , transforming growth factor ...

Подробнее
Номер записи: 10
17-01-2019 дата публикации

ELASTIC TISSUE MATRIX DERIVED HYDROGEL

Номер: US20190015457A1
Автор: Sun Wenquan, Wan Hua, Xu Hui
Принадлежит:

A tissue-derived hydrogel, as well as methods of making and using such hydrogels, are provided. 1. A tissue filler comprising:an arterial tissue matrix that has been treated with elastase to produce a swollen and softened arterial tissue matrix having a disrupted elastin network and in the form of a moldable putty that will conform to the shape of a space in which it is implanted, and wherein the arterial tissue matrix has an increased malleability after the elastase treatment as compared to the acellular tissue matrix prior to elastase treatment.2. The tissue filler of claim 1 , wherein the arterial tissue matrix is aortic tissue.3. The tissue filler of claim 2 , wherein the aortic tissue is porcine aortic tissue.4. The tissue filler of claim 1 , wherein the arterial tissue matrix is acellular.5. The tissue filler of claim 1 , wherein the elastase-treated arterial tissue matrix expands to a volume that is 200-300% larger than the volume of untreated arterial tissue when placed in an aqueous solution.6. The tissue filler of claim 4 , wherein the arterial tissue matrix can expand after implantation into a tissue to fill a space left by a tissue removal operation.7. The tissue filler of claim 1 , wherein the arterial tissue matrix is treated with elastase at a concentration of between 0.021 and 5.35 units per ml for 5 to 96 hours.8. A method of treating a tissue of the face or neck claim 1 , comprising:implanting a tissue filler into the tissue, wherein the tissue filler comprises an arterial tissue matrix from which some but not all of the elastin has been removed, and wherein the arterial tissue matrix used to prepare the tissue filler has been subjected to at least one round of freezing and thawing followed by removal of at least some elastin from the arterial tissue matrix, and wherein the arterial tissue matrix is not cross-linked prior to implantation.9. The method of claim 8 , wherein the treatment with elastase causes the arterial tissue matrix to ...

Подробнее
Номер записи: 11
17-01-2019 дата публикации

Vascular Extracellular Matrix Hydrogel

Номер: US20190015552A1
Автор: Badylak Stephen F., Fercana, Gleason Thomas G., JR. George R., Phillippi Julie Anne
Принадлежит:

Provided herein are methods of making an ECM gel from vascular tissue. Also provided herein are ECM compositions prepared from vascular tissue, and methods of use of those compositions, for example in treatment of aneurysms, and for vascularization or re-vascularization. 1. A method of preparing an extracellular matrix (ECM) material , comprising:a. incubating vascular adventitial tissue in a zwitterionic detergent;b. incubating the tissue in Trypsin-EDTA;c. incubating the tissue with an anionic detergent;d. disinfecting the tissue, optionally with peracetic acid, producing a decellularized ECM material;e. lyophilizing the decellularized ECM material;f. comminuting the decellularized ECM material;g. partially or completely solubilizing the decellularized ECM material with an acid protease to produce solubilized ECM; andh. neutralizing the solubilized ECM to produce an ECM pre-gel.2. The method of claim 1 , wherein the decellularized ECM material is not completely digested with the acid protease claim 1 , producing an ECM pre-gel that is able to gel at 37° C. comprising undigested decellularized ECM particles.3. The method of claim 1 , wherein the ECM material is prepared without a dialysis step or a crosslinking step.4. The method of claim 1 , wherein:a. the zwitterionic detergent is CHAPS;b. the anionic detergent is SDS;c. the acid protease is pepsin; ord. the decellularized ECM material is solubilized with an acid protease in a solution having a pH of from 1 to 4, from 1 to 2, or 2.0±0.3.5. The method of claim 1 , comprising dispersing the ECM material in a natural or a synthetic polymer composition claim 1 , optionally wherein the natural or a synthetic polymer composition is one or more of: a second ECM material claim 1 , fibrin claim 1 , collagen claim 1 , polyester (PE) claim 1 , polyurethane (PU) claim 1 , poly(ester urethane) urea (PEUU) claim 1 , poly(ether ester urethane) urea (PEEUU) claim 1 , poly(ester carbonate urethane)urea PECUU) claim 1 , poly( ...

Подробнее
Номер записи: 12
28-01-2016 дата публикации

Decellularization Method and System and Decellularized Tissue Formed Thereby

Номер: US20160022408A1
Автор: FERCANA GEORGE, SHAW ELIZA LAINE, Sierad Leslie, Simionescu Dan
Принадлежит:

Systems and methods that establish a pressure differential across a tissue wail to encourage complete decellularization of the wall are described. The methods can be utilized for decellularization of blood vessel tissue including heart valves and surrounding tissues. The methods and systems can essentially completely decellularize the treated tissue segments. Systems can be utilized to decellularize one or multiple tissue segments at a single time. 1. A method for decellularizing a tissue segment , the tissue segment including a lumen and a tissue wall surrounding the lumen , the tissue wall having an interior surface facing the lumen and an exterior surface that is opposite the interior surface the method comprising:contacting the interior surface of the tissue wall with a first decellularization solution;contacting the exterior surface of the tissue wall with a second decellularization solution;establishing a pressure differential across the tissue wall from the interior surface to the exterior surface for a period of time of about 1 minute or more, the pressure differential being from about 15 mmHg to about 150 mmHg;following the period of time, decreasing the pressure differential to a lower pressure differential across the tissue wall that is about 15 mmHg or less.2. The method of claim 1 , further comprising repeating the method one or more times.3. The method of claim 1 , wherein the period of time is about 5 minutes or less.4. The method of claim 1 , wherein the pressure differential is decreased to zero.5. The method of claim 1 , wherein the tissue segment is a vascular segment.6. The method of claim 1 , wherein the tissue segment comprises a heart valve in the lumen.7. The method of claim 1 , wherein the tissue segment comprises muscle tissue.8. The method of claim 1 , wherein the tissue segment comprises an aortic root.9. The method of claim 1 , wherein following the decrease in the pressure differential claim 1 , the tissue is held at the lower pressure ...

Подробнее
Номер записи: 13
28-01-2016 дата публикации

Tissue Prostheses for Repairing, Reconstructing and Replacing Damaged or Diseased Biological Structures and Associated Tissue

Номер: US20160022868A1
Автор: Robert G. Matheny
Принадлежит: Cormatrix Cardiovascular Inc

Non-antigenic, resilient, bioremodelable, biocompatible tissue prostheses that can be engineered into a variety of shapes and used to repair, augment, reconstruct or replace damaged or diseased biological structures and associated tissue.

Подробнее
Номер записи: 14
28-01-2016 дата публикации

CARDIAC OR VASCULAR TISSUE SPHEROID

Номер: US20160022870A1
Автор: Morita Shigeki, NAKAYAMA Koichi, NODE Koichi, NOGUCHI Ryo, TAMURA Tadashi
Принадлежит:

Provided is a method for producing a cardiac tissue spheroid or vascular tissue spheroid formed from a mixture of a myocardial cell or smooth muscle cell and at least one type of cell selected from a vascular endothelial cell and fibroblast, and a three dimensional cardiac tissue structure or three dimensional vascular tissue structure which are characterized by combining or laminating said spheroid. 1. A cardiac tissue spheroid formed from a mixture of cardiomyocytes and at least one type of cells selected from vascular endothelial cells and fibroblasts.2. The cardiac tissue spheroid according to claim 1 , formed from a mixture of cardiomyocytes claim 1 , vascular endothelial cells and fibroblasts.3. The cardiac tissue spheroid according to claim 2 , wherein the mixture ratio of the cardiomyocytes claim 2 , the vascular endothelial cells and the fibroblasts is such that the vascular endothelial cells are 10-60 and the fibroblasts are 10-60 to the cardiomyocytes of 100.4. A cardiac tissue spheroid obtained by fusing a spheroid formed from cardiomyocytes and a spheroid formed from at least one type of cells selected from vascular endothelial cells and fibroblasts.5. The cardiac tissue spheroid according to obtained by fusing a spheroid formed from cardiomyocytes claim 4 , a spheroid formed from vascular endothelial cells and a spheroid formed from fibroblasts.6. The cardiac tissue spheroid according to claim 5 , wherein the abundance ratio of the spheroid derived from cardiomyocytes claim 5 , the spheroid derived from vascular endothelial cells and the spheroid derived from fibroblasts is such that the spheroid derived from vascular endothelial cells is 10-60 and the spheroid derived from fibroblasts is 10-60 to the spheroid derived from cardiomyocytes of 100.7. A method for producing a three-dimensional cardiac tissue structure claim 5 , comprising the step of compounding or laminating the cardiac tissue spheroids according to or .8. The method according to claim 7 ...

Подробнее
Номер записи: 15
25-01-2018 дата публикации

HIGH SPEED 3D PRINTING SYSTEM FOR WOUND AND TISSUE REPLACEMENT

Номер: US20180021140A1
Автор: Angelini Thomas Ettor, Bhattacharjee Tapomoy, Chang Ya-Wen, Fernandez-Nieves Alberto, Marquez Samantha M., Rowe Kyle Gene, Sawyer Wallace Gregory
Принадлежит:

A method or apparatus for creating a three-dimensional tissue construct of a desired shape for repair or replacement of a portion of an organism. The method may comprise injecting at least one biomaterial in a three-dimensional pattern into a first material such that the at least one biomaterial is held in the desired shape of the tissue construct by the first material. The apparatus may comprise an injector configured to inject at least one biomaterial in a three-dimensional pattern into a first material such that the at least one biomaterial is held in the desired shape of the tissue construct by the first material. The first material may comprise a yield stress material, which may be a material exhibiting Herschel-Bulkley behavior. The tissue construct may have a smallest feature size of ten micrometers or less. 1. A method for creating a three-dimensional tissue construct of a desired shape for repair or replacement of tissue of a tissue cavity of an organism , the method comprising:injecting at least one biomaterial in a three-dimensional pattern into a first material such that the at least one biomaterial is held in the desired shape of the tissue construct by the first material.2. The method of claim 1 , further comprising:removing the injected at least one biomaterial from the first material.3. The method of claim 2 , wherein removing the injected at least one biomaterial from the first material comprises washing away the first material.4. The method of claim 2 , further comprising:inserting the tissue construct into the tissue cavity of the organism.5. The method of claim 2 , further comprising:attaching the tissue construct to the organism at the tissue cavity.6. The method of claim 1 , wherein:injecting the at least one biomaterial comprises injecting the at least one biomaterial such that the tissue construct has a smallest feature size of less than 1 millimeter7. The method of claim 6 , wherein injecting the at least one biomaterial comprises injecting ...

Подробнее
Номер записи: 16
28-01-2021 дата публикации

POLYMER-PERMEATED GRAFTS AND METHODS OF MAKING AND USING THE SAME

Номер: US20210023267A1
Автор: HEIM William, PASHOS Nicolas
Принадлежит:

This invention is directed to polymer-permeated grafts and methods of making and using the same. 1. An polymer-permeated graft for in vivo use in a subject comprising a tissue substantially free of cells , wherein the decellularized tissue is substantially free of water and is permeated with polymer , and wherein the polymer is substantially uniformly distributed in said tissue.2. The graft of claim 1 , wherein the graft comprises less than about 50% polymer.3. The graft of claim 2 , wherein the graft comprises about 0.1% to about 30% polymer.4. The graft of claim 1 , wherein the tissue comprises a dermal tissue and/or an epidermal tissue.5. The graft of claim 1 , wherein the tissue comprises an organ claim 1 , a muscle claim 1 , a ligament claim 1 , a bone claim 1 , a nipple claim 1 , areola claim 1 , a nipple attached to an areola claim 1 , a lip claim 1 , skin claim 1 , a tendon claim 1 , an aorta claim 1 , a blood vessel.6. The graft of claim 1 , wherein the tissue substantially retains at least one matrix molecule.7. The graft of claim 1 , wherein the matrix molecule comprises a component of the extracellular matrix.8. The graft of claim 1 , wherein the matrix molecule comprises laminin claim 1 , elastin claim 1 , fibronectin claim 1 , collagen claim 1 , or a combination thereof.9. The graft of claim 8 , wherein the collagen comprises a Type I collagen claim 8 , a Type III collagen claim 8 , a Type IV collagen claim 8 , a Type VI collagen claim 8 , or a combination thereof.10. The graft of claim 1 , wherein the tissue is substantially free of skin claim 1 , fat and/or fibrous tissue.11. The graft of claim 1 , wherein the polymer comprises a colored polymer.12. The graft of claim 11 , wherein the colored polymer comprises melanin claim 11 , a dye claim 11 , or a combination thereof.13. The graft of claim 1 , wherein the polymer comprises a natural polymer and/or a synthetic polymer.14. The graft of claim 1 , wherein the natural polymer comprises alginate or ...

Подробнее
Номер записи: 17
01-02-2018 дата публикации

BIOLOGICAL VALVE FOR VENOUS INSUFFICIENCY

Номер: US20180028723A1
Автор: JAFFE NORMAN
Принадлежит: HANCOCK JAFFE LABORATORIES, INC.

A bioprosthetic valve for repairing a deep venous insufficiency in a subject includes a single leaflet from a xenogeneic heart valve attached at natural margins of attachment to a patch of valve wall tissue. The patch may extend axially above and below the leaflet and circumferentially on either side of the leaflet to provide a region for attaching the patch to a fenestration in a host vein. A bioprosthetic valve may be manufactured by excising a portion of a xenogeneic heart valve including a single leaflet and contiguous wall tissue, and may further comprise shaving off excess leaflet tissue from adjacent leaflets. A method of replacing a malfunctioning venous valve in a subject includes providing a bioprosthetic valve as described above and inserting it to the host vein. 1. A method of providing a valve function in a host vein of a subject , the method comprising:providing a biological valve comprising a single leaflet xenogeneic heart valve tissue;attaching the single leaflet xenogeneic heart valve tissue at natural margins to a patch of contiguous tissue from the xenogeneic heart valve;inserting said replacement biological valve into said host vein at a patch site in the host vein; andsurrounding the host vein at the patch site with a tube attached to the patch.2. The method of claim 1 , further comprising creating a fenestration in the host vein claim 1 , the fenestration having a shape generally corresponding to the patch.3. The method of claim 1 , wherein the tube is created from a biological material.4. The method of claim 1 , wherein the tube is created from a nonbiological material.5. The method of claim 1 , wherein the leaflet need not completely obstruct the host vein.6. The method of claim 2 , further comprising attaching the replacement biological valve to the host vein at the fenestration.7. The method of claim 1 , further comprising removing at least one leaflet from the malfunctioning valve of the host vein.8. The method of claim 1 , wherein the ...

Подробнее
Номер записи: 18
30-01-2020 дата публикации

Prosthetic Valves And Related Inventions

Номер: US20200030088A1
Автор: Georg Lutter, Kemal Schankereli, Lucian Lozonschi, Robert Vidlund
Принадлежит: Tendyne Holdings Inc

This invention relates to the design and function of a compressible valve replacement prosthesis, collared or uncollared, which can be deployed into a beating heart without extracorporeal circulation using a transcatheter delivery system. The design as discussed focuses on the deployment of a device via a minimally invasive fashion and by way of example considers a minimally invasive surgical procedure preferably utilizing the intercostal or subxyphoid space for valve introduction. In order to accomplish this, the valve is formed in such a manner that it can be compressed to fit within a delivery system and secondarily ejected from the delivery system into the annulus of a target valve such as a mitral valve or tricuspid valve.

Подробнее
Номер записи: 19
07-02-2019 дата публикации

METHODS OF CONDITIONING SHEET BIOPROSTHETIC TISSUE

Номер: US20190038403A1
Автор: Campbell Louis A., Cohen Jeffrey S., Dove Jeffrey S., Jankovic Ivan, Migliazza John F., Schneider Ralph, Tian Bin, Wright Gregory A., Young James M.
Принадлежит:

Methods for the conditioning of bioprosthetic material employ bovine pericardial membrane. A laser directed at the fibrous surface of the membrane and moved relative thereto reduces the thickness of the membrane to a specific uniform thickness and smoothes the surface. The wavelength, power and pulse rate of the laser are selected which will smooth the fibrous surface as well as ablate the surface to the appropriate thickness. Alternatively, a dermatome is used to remove a layer of material from the fibrous surface of the membrane. Thinning may also employ compression. Stepwise compression with cross-linking to stabilize the membrane is used to avoid damaging the membrane through inelastic compression. Rather, the membrane is bound in the elastic compressed state through addition cross-linking. The foregoing several thinning techniques may be employed together to achieve strong thin membranes. 1. A method for preparing a bioprosthetic tissue membrane material , comprising:subjecting a collagenous tissue membrane to a glycerin-based treatment solution; andremoving at least a portion of material from a surface of the collagenous tissue membrane by ablating the collagenous tissue membrane with a laser, the surface of the collagenous tissue membrane having a smoothness;wherein the removing increases the smoothness of the surface of the collagenous tissue membrane.2. The method of claim 1 , wherein the collagenous tissue membrane is bovine pericardial tissue.3. The method of claim 2 , wherein the bovine pericardial tissue has a fibrous side and a smooth side.4. The method of claim 3 , wherein the surface of the collagenous tissue membrane is the fibrous side.5. The method of claim 1 , further comprising cross-linking the collagenous tissue membrane before the subjecting.6. The method of claim 1 , wherein the collagenous tissue membrane has opposite sides and a non-uniform thickness.7. The method of claim 6 , further comprising topographically mapping the collagenous ...

Подробнее
Номер записи: 20
07-02-2019 дата публикации

ALLOGENEIC MICROVASCULAR TISSUE FOR SOFT TISSUE TREATMENTS

Номер: US20190038805A1
Автор: EMMITT Richard B., Peterson Dale R.
Принадлежит:

Disclosed are products and methods for treating soft tissue injuries. The provided methods include the production of processed or cryopreserved microvascular tissue. Also provided are products and methods of using processed or cryopreserved microvascular tissue for the treatment of soft tissue injuries. 1. A method for repair or regeneration of a tissue selected from the group consisting of tendon , ligament , and skin , said method comprising applying a plurality of uncultured allogeneic stem or progenitor cells to said tissue and thereby effecting repair or regeneration of the tissue as compared to a control tissue to which uncultured allogeneic stem or progenitor cells are not applied.2. The method of claim 1 , wherein said plurality of uncultured allogeneic stem or progenitor cells are included in a processed or cryopreserved microvascular tissue.3. The method of claim 1 , wherein said plurality of uncultured allogeneic stem or progenitor cells comprise xenogeneic cells.4. The method of claim 1 , wherein said plurality of uncultured allogeneic stem or progenitor cells is less than 50% viable.5. The method of claim 1 , wherein said plurality of uncultured allogeneic stem or progenitor cells contains substantially no viable cells.6. A composition comprising a plurality of uncultured stem or progenitor cells formulated for implantation into an allogeneic or xenogeneic recipient claim 1 , said composition having tissue healing activity and comprising no bone or bone-derived matrix.7. The composition of claim 6 , wherein said plurality of uncultured allogeneic stem or progenitor cells are included in a processed or cryopreserved microvascular tissue.8. The composition of claim 6 , wherein said plurality of uncultured allogeneic stem or progenitor cells is less than 50% viable.9. The composition of claim 6 , wherein said plurality of uncultured stem or progenitor cells contains substantially no viable cells.10. The composition of claim 6 , wherein said composition is ...

Подробнее
Номер записи: 21
07-02-2019 дата публикации

ARTIFICIAL TISSUE PROGENITOR AND METHOD FOR PREPARING THE SAME

Номер: US20190038809A1
Автор: DU Mingchun, KANG Yujian James, ZUO Xiao
Принадлежит:

The invention relates to the technical filed of tissue engineering and 3D printing, particularly relates to an artificial tissue progenitor and a method for preparing the same. In particular, the invention relates to an artificial tissue progenitor comprising a solid support and a plurality of microcapsules, wherein at least one microcapsule is attached to the solid support, and the microcapsule comprises a cell and a biocompatible material encapsulating the cell, to a method for preparing the artificial tissue progenitor, to a kit and a package useful for preparing the artificial tissue progenitor, to an artificial tissue obtained by culturing the artificial tissue progenitor, such as an artificial lumen, to a lumen implant or a lumen model containing the artificial tissue progenitor or the artificial lumen, to use of the artificial tissue progenitor in the manufacture of an artificial tissue, a lumen implant or a lumen model, and to use of the artificial tissue in the manufacture of a lumen implant or lumen model. 1. An artificial tissue progenitor comprising a solid support and a plurality of microcapsules , wherein at least one microcapsule is attached to the solid support , and the microcapsule comprises a cell and a biocompatible material encapsulating the cell; the artificial tissue progenitor is a blood vessel progenitor.2. The artificial tissue progenitor of claim 1 , having one or more features selected from the following:(1) the artificial tissue progenitor is tubular;(2) the microcapsules each independently have a size of 100-500 μm;(3) the microcapsules are each independently spherical;(4) the microcapsule is in a gel state;(5) the microcapsules contain undifferentiated cells;(6) the cells in the microcapsules are adipose-derived mesenchymal stem cells;(7) the cells are obtained from a human, a monkey, a pig or a dog; and(8) the cells are derived from adipose tissue.3. The artificial tissue progenitor according to claim 1 , wherein the biocompatible ...

Подробнее
Номер записи: 22
06-02-2020 дата публикации

Prosthetic Valves And Related Inventions

Номер: US20200038179A1
Автор: Georg Lutter, Kemal Schankereli, Lucian Lozonschi, Robert Vidlund
Принадлежит: Tendyne Holdings Inc

This invention relates to the design and function of a compressible valve replacement prosthesis, collared or uncollared, which can be deployed into a beating heart without extracorporeal circulation using a transcatheter delivery system. The design as discussed focuses on the deployment of a device via a minimally invasive fashion and by way of example considers a minimally invasive surgical procedure preferably utilizing the intercostal or subxyphoid space for valve introduction. In order to accomplish this, the valve is formed in such a manner that it can be compressed to fit within a delivery system and secondarily ejected from the delivery system into the annulus of a target valve such as a mitral valve or tricuspid valve.

Подробнее
Номер записи: 23
06-02-2020 дата публикации

BIOPROSTHETIC TISSUE HAVING A REDUCED PROPENSITY FOR IN VIVO CALCIFICATION

Номер: US20200038554A1
Автор: Davidson James A., Dobler Darin P., Dove Jeffrey S.
Принадлежит:

A bioprosthetic tissue having a reduced propensity to calcify in vivo, the bioprosthetic tissue. The bioprosthetic tissue comprises an aldehyde cross-linked and stressed bioprosthetic tissue comprising exposed calcium, phosphate or immunogenic binding sites that have been reacted with a calcification mitigant. The bioprosthetic tissue has a reduced propensity to calcify in vivo as compared to aldehyde cross-linked bioprosthetic tissue that has not been stressed and reacted with the calcification mitigant. 1. A method of treating a cross-linked bioprosthetic tissue to reduce in vivo calcification , the method comprising:immersing a cross-linked bioprosthetic tissue in a solution comprising a calcification mitigant; andstressing the cross-linked bioprosthetic tissue by subjecting the cross-linked bioprosthetic tissue to pulsed fluid flow in the solution comprising the calcification mitigant;wherein the stressing produces localized micro collagen fibril damage at sites of flexion and acid binding sites; andwherein the calcification mitigant couples with the acid binding sites to produce capped acid binding sites.2. The method of claim 1 , wherein the calcification mitigant is one or more selected from the group consisting of: an amine claim 1 , an amino acid claim 1 , an amino sulfonate claim 1 , a hydrophilic multifunctional polymer claim 1 , a hydrophobic multifunctional polymer claim 1 , an α-dicarbonyl claim 1 , a hydrazide claim 1 , an N claim 1 ,N-disuccinimidyl carbonate claim 1 , a carbodiimide claim 1 , a 2-chloro-1-methylpyridinium iodide (CMPI) claim 1 , an antibiotic claim 1 , a cell recruiting agent claim 1 , a hemocompatibility agent claim 1 , an anti-inflammatory agent claim 1 , an anti-proliferative agent claim 1 , an immunogenic suppressing agent claim 1 , a reducing agent claim 1 , and a mono- claim 1 , di- or polyepoxy alkane.3. The method of claim 2 , wherein:the calcification mitigant is an amine; andthe amine is an ethanolamine.4. The method of ...

Подробнее
Номер записи: 24
06-02-2020 дата публикации

Methods of preparing personalized blood vessels

Номер: US20200038555A1
Автор: Raimund Strehl
Принадлежит: VeriGraft AB

The present disclosure relates to methods of preparing personalized blood vessels, useful for transplantation with improved host compatibility and reduced susceptibility to thrombosis. Also provided are personalized blood vessels produced by the methods and use thereof in surgery.

Подробнее
Номер записи: 25
25-02-2021 дата публикации

CARDIOSPHERE-DERIVED CELL SHEET AND METHODS OF MAKING AND USING THE SAME

Номер: US20210054341A1
Автор: Suzuki Gen
Принадлежит:

A method of making a cell sheet comprising secondary spheroids, including (a) obtaining cardiosphere-derived cells; (b) cultivating the cardiosphere-derived cells for a first period of time in a first media comprising at least one of an ascorbic acid and an analog thereof, to form secondary spheroids; (c) transferring an amount of the spheroids formed in step (b) into a mold; (d) culturing the secondary spheroids for a second period of time in a second media comprising at least one of the ascorbic acid and an analog thereof, wherein the at least one of the ascorbic acid and an analog thereof is present in an amount effective to promote a formation of an extracellular matrix; and (e) culturing a product obtained in step (d) for a third period of time, in the absence of the at least one of the ascorbic acid and an analog thereof. 1. A method of making a cell sheet comprising secondary spheroids , comprising:(f) obtaining cardiosphere-derived cells;(g) cultivating the cardiosphere-derived cells for a first period of time in a first media comprising at least one of an ascorbic acid and an analog thereof, to form secondary spheroids;(h) transferring an amount of the spheroids formed in step (b) into a mold;(i) culturing the secondary spheroids for a second period of time in a second media comprising at least one of the ascorbic acid and an analog thereof, wherein the at least one of the ascorbic acid and an analog thereof is present in an amount effective to promote a formation of an extracellular matrix; and(j) culturing a product obtained in step (d) for a third period of time, in the absence of the at least one of the ascorbic acid and an analog thereof.2. The method of claim 1 , wherein the first period of time is about 24 hours.3. The method of claim 1 , wherein the second period of time is about 3 days.4. The method of claim 1 , wherein the third period of time is about 4 days.5. The method of claim 1 , wherein a total of the second and third periods of times is ...

Подробнее
Номер записи: 26
10-03-2022 дата публикации

Method for preparing biological tissue for surgical implantation

Номер: US20220072202A1
Автор: Guilherme Agreli, Katharina Kiss
Принадлежит: P+F Products and Features GmbH

The present invention relates to a method for treating biological tissue and a biological tissue obtained by the treatment method, and specifically to a method for treating biological tissue so as to suppress the calcification, risk of biofilm adherent over pericardium and strength reduction of the tissue due to treatment. The invention is also directed to bioprosthesis and transcatheter heart valves containing the biological tissue.

Подробнее
Номер записи: 27
01-03-2018 дата публикации

MULTI-PORTION REPLACEMENT HEART VALVE PROSTHESIS

Номер: US20180055629A1
Автор: Cooper Alexander H., Landon David Robert, Oba Travis Zenyo, Peterson Matthew A., Rabito Glen T., Ratz J. Brent, Yi Seung-Beom
Принадлежит: EDWARDS LIFESCIENCES CORPORATION

A replacement mitral valve prosthesis includes a support structure and a valve body having three flexible leaflets. The support structure preferably includes an internal valve frame and an external sealing frame. The valve frame supports the flexible leaflets. The sealing frame is adapted to conform to the shape of the native mitral valve annulus. The sealing frame may be coupled to an inlet end of the valve frame, an outlet end of the valve frame, or both. A plurality of anchors are coupled to the outlet end of the valve frame. The anchors extend radially outwardly for placement behind native leaflets. The prosthesis preferably includes a skirt disposed along an exterior of the external sealing frame. The prosthesis is collapsible for delivery into the heart via a delivery catheter. The prosthesis is configured to self-expand for deployment in the heart when released from the delivery catheter. 1. A replacement heart valve prosthesis , the prosthesis comprising: [ the first anchoring feature extends radially outwardly from the first lower region; and', 'at least a portion of the first anchoring feature extends towards the first upper region; and, 'a first frame portion comprising a first frame body and a first anchoring feature, the first frame body comprising a first upper region, a first intermediate region, and a first lower region, wherein, when the prosthesis is in an expanded configuration, at least a portion of the second upper region extends radially outwardly from the first upper region;', 'the second lower region is positioned radially between the first anchoring feature and the first frame body; and', 'the second intermediate portion is configured such that, when the prosthesis is deployed within the native heart valve, the second intermediate portion is positioned within a native valve annulus; and, 'a second frame portion positioned radially outward of the first frame body, the second frame portion comprising a second frame body having a second upper ...

Подробнее
Номер записи: 28
21-02-2019 дата публикации

PERICARDIAL SEALING MEMBER FOR PROSTHETIC HEART VALVE

Номер: US20190053895A1
Автор: Levi Tamir S.
Принадлежит:

In one embodiment, a delivery assembly can comprise an annular frame, a leaflet structure positioned within the frame and secured thereto, and an outer skirt positioned around an outer surface of the frame. The annular frame can comprise an inflow end and an outflow end and can be radially collapsible and expandable between a radially collapsed configuration and a radially expanded configuration. The outer skirt can comprise pericardial tissue having a fibrous parietal layer defining a first surface of the outer skirt and a serous parietal layer defining a second surface of the outer skirt. The outer skirt can be positioned such that the first surface is facing away from the frame and the second surface is facing towards the frame. 1. An implantable prosthetic valve comprising:an annular frame comprising an inflow end and an outflow end and being radially collapsible and expandable between a radially collapsed configuration and a radially expanded configuration;a leaflet structure positioned within the frame and secured thereto; andan outer skirt positioned around an outer surface of the frame, wherein the outer skirt comprises pericardial tissue having a fibrous parietal layer defining a first surface of the outer skirt and a serous parietal layer defining a second surface of the outer skirt, and wherein the outer skirt is positioned such that the first surface is facing away from the frame and the second surface is facing towards the frame.2. The prosthetic valve of claim 1 , wherein the outer skirt comprises bovine pericardial tissue.3. The prosthetic valve of claim 1 , wherein the outer skirt is laser milled to reduce its thickness.4. The prosthetic valve of claim 1 , wherein the thickness of the outer skirt is between 50 μm and 150 μm.5. The prosthetic valve of claim 1 , wherein the outer skirt comprises a plurality of openings or slits.6. The prosthetic valve of claim 5 , wherein at least one of the openings or slits is elongated in an axial direction.7. The ...

Подробнее
Номер записи: 29
03-03-2016 дата публикации

ANTI-THROMBOGENIC GRAFTS

Номер: US20160058913A1
Автор: DIMITRIEVSKA Sashka, Niklason Laura
Принадлежит:

The present invention provides anti-thrombogenic compositions, including anti-thrombogenic vascular grafts. In certain embodiments, the compositions comprise decellularized tissue coated with an anti-thrombogenic coating. The present invention also provides methods of preparing anti-thrombogenic compositions and methods of treatment comprising implanting the anti-thrombogenic compositions into a subject in need thereof. 1. A composition comprising a substrate having at least one surface coated with an anti-thrombogenic coating.2. The composition of claim 1 , wherein the anti-thrombogenic coating comprises a first layer comprising a hydrogel.3. The composition of claim 2 , wherein the first layer comprises hyaluronic acid.4. The composition of claim 3 , wherein the hyaluronic acid is thiol-modified hyaluronic acid.5. The composition of claim 2 , wherein the first layer is crosslinked to the at least one surface of the substrate.6. The composition of claim 2 , wherein the anti-thrombogenic coating further comprises a second layer comprising an anti-coagulant claim 2 , wherein the second layer is crosslinked to the first layer.7. The composition of claim 6 , wherein the second layer comprises heparin.8. The composition of claim 1 , wherein the substrate is decellularized tissue.9. The composition of claim 8 , wherein the decellularized tissue is a decellularized blood vessel having a luminal surface claim 8 , and wherein the anti-thrombogenic coating is coated on the luminal surface of the decellularized blood vessel.10. A method of preparing a graft coated with an anti-thrombogenic coating claim 8 , comprising the steps of:providing a substrate having at least one surface; and applying a first crosslinking solution to the surface; and', 'applying a hydrogel solution to the surface, thereby providing a first layer on the surface of the substrate., 'coating the at least one surface with an anti-thrombogenic coating, wherein said step of coating comprises11. The method ...

Подробнее
Номер записи: 30
01-03-2018 дата публикации

BIOENGINEERED ALLOGENEIC BLOOD VESSEL

Номер: US20180055973A1
Автор: Olausson Michael, Sumitran-Holgersson Suchitra
Принадлежит:

The present invention relates to methods for recellurization of blood vessels. This method is particularly useful for producing an allogeneic vein, wherein a donor vein is decellularized and then recellularized using whole blood or bone marrow stem cells. The allogeneic veins produced by the methods disclosed herein are particularly advantageous for implantation or transplantation into patients with vascular diseases. 1. A method of recellularizing a blood vessel comprising introducing endothelial cells and smooth muscle cells and/or progenitor cells for endothelial and smooth muscle cells to the lumen of a decellularized blood vessel and culturing said population of cells on the decellularized blood vessel , thereby recellularizing the blood vessel.2. The method of claim 1 , wherein said cells are from peripheral or whole blood or from bone marrow.3. The method of claim 1 , wherein said cells are introduced as whole blood.4. The method of claim 1 , wherein said cells are expanded and differentiated into endothelial cells and smooth muscle cells in vitro prior to introducing the endothelial cells and the smooth muscle cells to the decellularized blood vessel.5. The method of claim 1 , wherein said introducing the cells to the decellularized blood vessel is by injection or perfusion.6. The method of claim 1 , wherein said culturing comprises perfusion of endothelial cell medium and/or smooth muscle cell medium.7. The method of claim 6 , wherein said perfusion of said endothelial cell medium and said smooth muscle cell medium are administered in alternation.8. The method of claim 7 , wherein said administration in alternation is repeated at least twice.9. The method of claim 1 , wherein said culturing the cells on the decellularized blood vessel results in proliferation and/or differentiation of the cells to endothelial cells and smooth muscle cells.10. The method of claim 9 , wherein said endothelial cells line the inner lining or the lumen of the decellularized ...

Подробнее
Номер записи: 31
20-02-2020 дата публикации

SURGICAL METHODS OF REPLACING PROSTHETIC HEART VALVES

Номер: US20200054450A1
Автор: Bakis George, Bash Assaf, Benichou Netanel, Bourang Henry, Keidar Yaron, Rowe Stanton J., Spenser Benjamin, Wood Larry L.
Принадлежит:

A two-stage or component-based valve prosthesis that can be quickly and easily implanted during a surgical procedure is provided. The prosthetic valve comprises a support structure that is deployed at a treatment site. The prosthetic valve further comprises a valve member configured to be quickly connected to the support structure. The support structure may take the form of a stent that is expanded at the site of a native valve. If desired, the native leaflets may remain and the stent may be used to hold the native valve open. In this case, the stent may be balloon expandable and configured to resist the powerful recoil force of the native leaflets. The support structure is provided with a coupling means for attachment to the valve member, thereby fixing the position of the valve member in the body. The valve member may be a non-expandable type, or may be expandable from a compressed state to an expanded state. The system is particularly suited for rapid deployment of heart valves in a conventional open-heart surgical environment. 1providing an expandable anchoring member having a generally tubular expandable body, the anchoring member being adapted to be constricted to a collapsed state for advancement through the vasculature and adapted to be enlarged to an expanded state sized for contacting the heart valve annulus;providing a prosthetic valve member sized to be supported within the anchoring member, the prosthetic valve member including a metallic support structure and three leaflets configured to permit flow in an outflow direction through the prosthetic valve member;creating a direct access pathway through an apex of the heart;delivering the anchoring member to a position within the heart valve annulus while the anchoring member is in the collapsed state; andenlarging the anchoring member to the expanded state and into contact with the heart valve annulus;wherein the prosthetic valve member is supported within the anchoring member during use and the leaflets ...

Подробнее
Номер записи: 32
17-03-2022 дата публикации

METHODS OF IMPLANTING A DRY BIOPROSTHETIC VALVED CONDUIT

Номер: US20220079752A1
Автор: Bobo, Campbell Louis A., Cheung Tak G., JR. Donald E., Wright Gregory A.
Принадлежит:

A valved conduit including a bioprosthetic valve, such as a heart valve, and a tubular conduit sealed with a bioresorbable material. The bioprosthetic heart valve includes prosthetic tissue that has been treated such that the tissue may be stored dry for extended periods without degradation of functionality of the valve. The bioprosthetic heart valve may have separate bovine pericardial leaflets or a whole porcine valve. The sealed conduit includes a tubular matrix impregnated with a bioresorbable medium such as gelatin or collagen. The valved conduit is stored dry in packaging in which a desiccant pouch is supplied having a capacity for absorbing moisture within the packaging limited to avoid drying the bioprosthetic tissue out beyond a point where its ability to function in the bioprosthetic heart valve is compromised. The heart valve may be sewn within the sealed conduit or coupled thereto with a snap-fit connection. 1. A method of preparing and delivering a valved conduit , comprising:removing a pre-assembled valved conduit from a dry package in which the valved conduit is stored without a preserving solution, the valved conduit including a bioprosthetic heart valve coupled to a conduit, the heart valve having leaflets of bioprosthetic tissue and the conduit being sealed with a bioresorbable medium; anddelivering and securing the valved conduit to an implantation site.2. The method of claim 1 , wherein the conduit is secured to the bioprosthetic valve using sutures.3. The method of claim 2 , wherein the heart valve has a suture-permeable sewing ring surrounding an inflow end thereof claim 2 , wherein an inlet end of the conduit is secured to the sewing ring with sutures.4. The method of claim 3 , wherein the heart valve has commissure posts between which the leaflets are supported and a sewing ring claim 3 , and the heart valve couples to the conduit with the commissure posts inside the conduit and the sewing ring outside the conduit.5. The method of claim 1 , ...

Подробнее
Номер записи: 33
27-02-2020 дата публикации

LOW GRADIENT PROSTHETIC HEART VALVES

Номер: US20200060812A1
Автор: Cao Hengchu, Sun Wei
Принадлежит:

A low pressure gradient prosthetic heart valve for implant in a human. The valve includes a support frame with undulating inflow cusps and outflow commissure posts to which flexible leaflets attach and coapt in a flow area. The commissure posts angle outward in a neutral state to widen the outflow orifice area. Also, the leaflets are designed to fit within the support frame and expand outward in a valve open state without creating a shelf or belly that would restrict flow. 1. A low pressure gradient prosthetic heart valve , comprising:a support frame including a leaflet attachment edge with an undulating shape defined by alternating arcuate inflow cusp regions and on an inflow end and arcuate outflow commissure posts on an outflow end, the support frame, in a relaxed state, circumscribing a flow volume having a central axis, the flow volume having a maximum flow orifice area perpendicular to the central axis limited by the inflow end of the support frame; anda plurality of flexible bovine pericardial leaflets attached to the support frame and extending inward toward the axis, each leaflet having an arcuate cusp edge with no straight portions opposite a free edge and opposed attachment tabs therebetween, wherein the cusp edge conforms to a corresponding support frame cusp region and attaches therealong between adjacent commissure posts, and a free edge that coapts with the free edges of the other leaflets to provide one way flow through the valve, wherein the cusp edge is defined by a complex curve of multiple radii;wherein when the valve opens the free edges of the leaflets move outward toward the support frame from fluid flow in an outflow direction and corresponding fluid pressures, and wherein each leaflet has a size and is attached to the corresponding support frame cusp region such that when the valve opens the leaflets spread outward to provide an outflow orifice area that is no less than the maximum flow orifice area.2. The heart valve of claim 1 , wherein ...

Подробнее
Номер записи: 34
27-02-2020 дата публикации

METHODS OF PREPARING AND DELIVERING A DRY BIOPROSTHETIC VALVED CONDUIT

Номер: US20200060816A1
Автор: Bobo, Campbell Louis A., Cheung Tak G., JR. Donald E., Wright Gregory A.
Принадлежит:

A valved conduit including a bioprosthetic valve, such as a heart valve, and a tubular conduit sealed with a bioresorbable material. The bioprosthetic heart valve includes prosthetic tissue that has been treated such that the tissue may be stored dry for extended periods without degradation of functionality of the valve. The bioprosthetic heart valve may have separate bovine pericardial leaflets or a whole porcine valve. The sealed conduit includes a tubular matrix impregnated with a bioresorbable medium such as gelatin or collagen. The valved conduit is stored dry in packaging in which a desiccant pouch is supplied having a capacity for absorbing moisture within the packaging limited to avoid drying the bioprosthetic tissue out beyond a point where its ability to function in the bioprosthetic heart valve is compromised. The heart valve may be sewn within the sealed conduit or coupled thereto with a snap-fit connection. 1. A method of preparing and delivering a valved conduit , comprising:procuring a pre-assembled valved conduit including a prosthetic heart valve having bioprosthetic tissue that has been treated such that the tissue may be stored dry for extended periods without degradation of functionality of the valve, the valve being coupled to a conduit sealed with a bioresorbable medium so as to provide the valved conduit and stored in a dry package including at least one sterile container in which the valved conduit is stored without a preserving solution;opening the dry package and removing the valved conduit; anddelivering the valved conduit to an implantation site.2. The method of claim 1 , wherein the conduit is secured to the bioprosthetic valve using sutures.3. The method of claim 1 , wherein the bioprosthetic valve couples within the conduit such that the conduit extends on both ends of the valve to provide both inflow and outflow extensions.4. The method of claim 1 , wherein the bioprosthetic valve is a heart valve and includes bovine pericardial ...

Подробнее
Номер записи: 35
27-02-2020 дата публикации

METHOD FOR PROTECTING SKELETONIZED BLOOD VESSELS

Номер: US20200061244A1
Автор: Akins Robert, Kiick Kristi L., ROBINSON Karyn, SCOTT Rebecca
Принадлежит:

Skeletonized blood vessels for use as vascular grafts are protected from biomechanical injury and/or certain cellular and extracellular changes by application of a biocompatible hydrogel to the vessel exterior. The hydrogel may be applied to the vessel graft before or after harvesting from a donor patient. 1. A method for protecting a skeletonized blood vessel , comprising forming a coating on at least a portion of an outer surface of the blood vessel , wherein the coating comprises a biocompatible hydrogel.2. The method according to claim 1 , wherein the blood vessel is a vein.3. The method according to claim 1 , wherein the blood vessel is an artery.4. The method according to claim 1 , wherein the blood vessel is selected from the group consisting of aortas claim 1 , carotid arteries claim 1 , coronary arteries claim 1 , internal mammary arteries claim 1 , internal thoracic arteries claim 1 , radial arteries claim 1 , femoral arteries claim 1 , gastroepiploic arteries claim 1 , popliteal arteries claim 1 , and saphenous veins.5. The method according to claim 4 , wherein the blood vessel is an internal thoracic artery.6. The method according to claim 4 , wherein the blood vessel is a saphenous vein.7. The method according to claim 4 , wherein the blood vessel is a radial artery.8. The method according to claim 4 , wherein the blood vessel is a gastroepiploic artery.9. The method according to any one of - claim 4 , wherein the blood skeletonized vessel is harvested from a donor claim 4 , further comprising depositing the coating on the outer surface of the blood vessel in the donor before harvesting.10. The method according to claim 9 , wherein the donor is a patient who receives the protected skeletonized vessel.11. The method according to any one of - claim 9 , further comprising delivering to the outer surface a composition comprising two or more hydrogel precursor reactants claim 9 , whereby the two or more hydrogel precursor reactants react and form the ...

Подробнее
Номер записи: 36
09-03-2017 дата публикации

PROSTHETIC HEART VALVE INCLUDING STENT STRUCTURE AND TISSUE LEAFLETS, AND RELATED METHODS

Номер: US20170065413A1
Автор: Allan Bob, Ashworth Paul E., Braido Peter N., Cai Chad, Kruse Steven D., LaChance Lise
Принадлежит: ST. JUDE MEDICAL, INC.

A method of making a prosthetic heart valve may include providing an annular stent having a plurality of annularly spaced commissure portions having tips, covering each of the tips with a first fabric cover, covering the first fabric covers and the remainder of the stent with a second fabric cover, covering the second fabric cover with a first tissue membrane, and covering the outside of the first tissue membrane with a second tissue membrane, the second tissue membrane forming leaflet portions that extend inwardly between the commissure portions. 1. (canceled)2. A prosthetic heart valve , comprising:an annular stent having an inner side, an outer side, an inflow edge and an outflow edge;a first fabric cover over a portion of the outflow edge, the first fabric cover not extending to a remainder of the annular stent;a second fabric cover that extends over the first fabric cover and over the remainder of the inner side of the annular stent and the outer side of the annular stent;a first tissue membrane covering the second fabric cover; anda second tissue membrane that surrounds the first tissue membrane on the outer side of the stent.3. The prosthetic heart valve as claimed in claim 2 , wherein the stent is made of metal.4. The prosthetic heart valve as claimed in claim 2 , wherein the stent is made of polymer.5. The prosthetic heart valve as claimed in claim 2 , wherein the first tissue membrane comprises mammalian pericardium.6. The prosthetic heart valve as claimed in claim 2 , wherein the second tissue membrane comprises mammalian pericardium.7. The prosthetic heart valve as claimed in claim 2 , further comprising a sewing cuff positioned adjacent the inflow edge of the stent.8. The prosthetic heart valve as claimed in claim 7 , wherein the inflow edge of the stent has a shape claim 7 , and the sewing cuff has a shape corresponding to the shape of the inflow edge of the stent.9. The prosthetic heart valve as claimed in claim 7 , wherein the inflow edge has a ...

Подробнее
Номер записи: 37
09-03-2017 дата публикации

TISSUE MODIFICATION DEVICES, SYSTEMS, AND METHODS

Номер: US20170065744A1
Автор: Anderson-Cunanan Crystal Marie, Byron Mary M., FOSTER DANIEL J., McCarthy Ray, SWEHLA BRADLEY S., Wulfman David Robert
Принадлежит:

A tissue modification apparatus includes at least a first plurality of grippers aligned in a plane adapted to secure a first edge of a patch of tissue. The plurality of grippers are each secured to a first force actuator. The first plurality of grippers are each adapted to pivot relative to the first force actuator about an axis perpendicular to the plane. In some cases, a plurality of grippers are attached to a force actuator by a passive force transfer mechanism. In some cases, individual force actuators are attached by pivoted connections to individual grippers. Methods of treating tissue can secure tensioned tissue to a frame to retain the tension during a treatment (e.g., cross-linking the tissue with a chemical cross-linker). 1. A tissue modification apparatus comprising at least a first plurality of grippers aligned in a plane adapted to secure a first edge of a patch of tissue , the plurality of grippers each being secured to a first force actuator , the first plurality of grippers each being adapted to pivot relative to the first force actuator about an axis perpendicular to the plane.2. The tissue modification apparatus of claim 1 , further comprising a second plurality of grippers aligned in the plane opposite the first plurality of grippers claim 1 , the second plurality of grippers being adapted to secure a second edge of a patch of tissue claim 1 , the second plurality of grippers each being adapted to pivot about an axis perpendicular to the plane claim 1 , the first plurality of grippers being adapted to pull the tissue in a direction opposite the second plurality of grippers such that a patch of tissue secured between the first and second plurality of grippers can be stretched along a first orientation.3. The tissue modification apparatus of claim 2 , wherein the second plurality of grippers are each secured to a second force actuator via pivoted connections such that the first and second force actuators are adapted to pull the first and second ...

Подробнее
Номер записи: 38
12-03-2015 дата публикации

SINGLE-PASS ENDOSCOPIC VESSEL HARVESTING

Номер: US20150073207A1
Автор: Langford Robert R.
Принадлежит:

An endoscopic harvesting device removes a vessel from a body. The vessel has an anterior side closest to the skin. A sheath extends in a longitudinal direction with a dissector tip for advancing along the vessel substantially along the anterior side to create a flanking tunnel spaced away from the vessel. A ring-shaped blade is mounted to the sheath and is disposed in a plane substantially perpendicular to the longitudinal direction and proximal of the dissector tip. The blade forms a lateral loop to encircle the vessel from the flanking tunnel and to make a vasiform cut including a pedicle around the vessel as the sheath advances. 1. Apparatus for endoscopic harvesting of a vessel from a body , wherein the vessel has an anterior side closest to the skin , comprising:a sheath extending in a longitudinal direction with a dissector tip for advancing along the vessel substantially along the anterior side to create a flanking tunnel spaced away from the vessel; anda ring-shaped blade mounted to the sheath and disposed in a plane substantially perpendicular to the longitudinal direction and proximal of the dissector tip, wherein the blade forms a lateral loop to encircle the vessel from the flanking tunnel and to make a vasiform cut including a pedicle around the vessel as the sheath advances.2. The apparatus of wherein the vessel has a plurality of side branches claim 1 , and wherein the blade has a leading edge that cuts and cauterizes the side branches as the sheath advances.3. The apparatus of wherein the blade comprises an ultrasonic cutter at the leading edge.4. The apparatus of wherein the blade is comprised of a partial ring with an open end of the lateral loop being adapted to be initially inserted around the vessel by rotating the blade to puncture tissue around the vessel and the surrounding pedicle claim 1 , so that the vessel remains unsevered while the vasiform cut is made.5. The apparatus of further comprising an endoscopic lens secured to the sheath for ...

Подробнее
Номер записи: 39
15-03-2018 дата публикации

Compositions and methods for cardiac therapy

Номер: US20180071432A1
Автор: Adam Kinsey, Jennifer Singelyn, Jessica Dequach, Karen Christman
Принадлежит: UNIVERSITY OF CALIFORNIA, Ventrix Inc

Provided herein are methods and compositions for cardiac therapy. Such compositions include extracellular-matrix (ECM)-based products that can be used to support tissue repair. The compositions can be used for various purposes. In some cases, they can be introduced into a subject in order to preserve and/or repair damaged heart tissue.

Подробнее
Номер записи: 40
07-03-2019 дата публикации

PRE-ASSEMBLED PACKAGED BIOPROSTHETIC VALVE CONDUIT

Номер: US20190069999A1
Автор: Bobo, Campbell Louis A., Cheung Tak G., JR. Donald E., Wright Gregory A.
Принадлежит:

A valved conduit including a bioprosthetic valve, such as a heart valve, and a tubular conduit sealed with a bioresorbable material. The bioprosthetic heart valve includes prosthetic tissue that has been treated such that the tissue may be stored dry for extended periods without degradation of functionality of the valve. The bioprosthetic heart valve may have separate bovine pericardial leaflets or a whole porcine valve. The sealed conduit includes a tubular matrix impregnated with a bioresorbable medium such as gelatin or collagen. The valved conduit is stored dry in packaging in which a desiccant pouch is supplied having a capacity for absorbing moisture within the packaging limited to avoid drying the bioprosthetic tissue out beyond a point where its ability to function in the bioprosthetic heart valve is compromised. The heart valve may be sewn within the sealed conduit or coupled thereto with a snap-fit connection. 1. A pre-assembled , packaged valved conduit , comprising:a bioprosthetic valve including bioprosthetic tissue, the valve having been treated such that the bioprosthetic tissue has less than 70% water content and may be stored dry for extended periods without degradation of functionality of the valve;a conduit sealed with a bioresorbable medium to which the bioprosthetic valve is coupled so as to provide the valved conduit; anddry packaging for the valved conduit including at least one sterile container in which the valved conduit is stored without a preserving solution.2. The valved conduit of claim 1 , wherein the conduit is secured to the bioprosthetic valve using sutures.3. The valved conduit of claim 1 , wherein the bioprosthetic valve is a heart valve and includes bovine pericardial leaflets claim 1 , and the conduit comprises a tubular matrix impregnated with collagen.4. The valved conduit of claim 1 , wherein the tissue has been cross-linked using glutaraldehyde or other aldehyde containing agents claim 1 , treated with a capping agent claim ...

Подробнее
Номер записи: 41
16-03-2017 дата публикации

Device for tendon and ligament treatment

Номер: US20170071723A1
Автор: Gary Monteiro, Wenquan Sun
Принадлежит: LifeCell Corp

Devices and methods for treating defects in connective tissue are provided along with methods for making such devices. The devices can include acellular arterial tissue matrices that facilitate regrowth of the damaged tissue.

Подробнее
Номер записи: 42
16-03-2017 дата публикации

METHODS OF CONDITIONING SHEET BIOPROSTHETIC TISSUE

Номер: US20170071731A1
Автор: Campbell Louis A., Cohen Jeffrey S., Dove Jeffrey S., Jankovic Ivan, Migliazza John F., Schneider Ralph, Tian Bin, Wright Gregory A., Young James M.
Принадлежит:

Methods for the conditioning of bioprosthetic material employ bovine pericardial membrane. A laser directed at the fibrous surface of the membrane and moved relative thereto reduces the thickness of the membrane to a specific uniform thickness and smoothes the surface. The wavelength, power and pulse rate of the laser are selected which will smooth the fibrous surface as well as ablate the surface to the appropriate thickness. Alternatively, a dermatome is used to remove a layer of material from the fibrous surface of the membrane. Thinning may also employ compression. Stepwise compression with cross-linking to stabilize the membrane is used to avoid damaging the membrane through inelastic compression. Rather, the membrane is bound in the elastic compressed state through addition cross-linking. The foregoing several thinning techniques may be employed together to achieve strong thin membranes. 1. A method for preparing a bioprosthetic tissue comprising:treating a bioprosthetic tissue with a first fixative to at least partially fix the tissue;treating the bioprosthetic tissue with a collagen preserving agent; andreducing a thickness of a pre-determined portion of the bioprosthetic tissue to produce a contoured bioprosthetic tissue having at least two areas of different thicknesses.2. The method of claim 1 , wherein the first fixative is an aldehyde.3. The method of claim 2 , wherein the aldehyde is a glutaraldehyde or a formaldehyde.4. The method of claim 1 , wherein the first fixative is a 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) or a polyethylene glycol.5. The method of claim 1 , wherein the thickness of the pre-determined portion of the bioprosthetic tissue is in the range of about 150 microns to about 250 microns.6. The method of claim 1 , wherein the thickness of the pre-determined portion of the bioprosthetic tissue is about 100 microns.7. The method of claim 1 , wherein the reducing is performed with a laser.8. The method of claim 7 , wherein the ...

Подробнее
Номер записи: 43
16-03-2017 дата публикации

Bioengineered Allogeneic Valve

Номер: US20170071738A1
Автор: Hisdal Jonny, Rosales Antonio, Sumitran-Holgersson Suchitra
Принадлежит:

The present disclosure relates to methods for recellularization of valves in valve-bearing veins. This method is useful for producing an allogeneic venous valve, wherein a donor valve-bearing vein is decellularized and then recelluiarized using whole blood or bone marrow stem cells. The allogeneic valves produced by the methods disclosed herein are advantageous for implantation, transplantation, or grafting into patients with vascular diseases. 1. A method of recellularization of a valve in a vein , comprising introducing blood comprising progenitor cells for endothelial cells and progenitor cells for smooth muscle cells to the lumen of a decellularized vein , and culturing the cells in the lumen of the decellularized vein , thereby recellularizing the valve in the vein.2. The method of claim 1 , wherein the blood is peripheral venous blood or whole blood.3. The method of claim 2 , wherein the peripheral venous blood or the whole blood is introduced to the decellularized vein by injection or perfusion.4. The method of claim 3 , further comprising culturing the cells by perfusion of endothelial cell medium and smooth muscle cell medium.5. The method of claim 4 , wherein the perfusion of the endothelial cell medium and the smooth muscle cell medium are in alternation.6. The method of one of the above claims claim 4 , wherein the recellularized valve is CD31 positive claim 4 , vWF positive claim 4 , smooth muscle actin positive claim 4 , and has nuclei.7. The method of one of the above claims claim 4 , wherein the recellularized valve has mechanical properties of withstanding force at first peak at or above 0.8 N.8. The method of one of the above claims claim 4 , wherein the recellularized valve has a closure time of equal to or less than 0.5 seconds.9. A method of treating chronic venous insufficiency (CVI) claim 4 , deep vein thrombosis (DVT) claim 4 , and/or leg ulceration in a subject in need thereof claim 4 , comprising introducing a recellularized valve-bearing ...

Подробнее
Номер записи: 44
05-03-2020 дата публикации

Anticalcification Treatment For Impantable Biological Tissues Using Calcitonin

Номер: US20200069842A1
Автор: Agathos Efstathios-Andreas
Принадлежит:

This invention relates to the field of surgical implants, and in particular to a method of treating biomedical material, and more particularly bioprosthetic heart valves and tracheas, to mitigate calcification when implanted in a mammalian body. 1. A method for treating biological tissue , comprising exposing said tissue to a mixture of a fixative and Calcitonin in solution so as to create treated biological tissue.2. The method of claim 1 , wherein the fixative is glutaraldehyde.3. The method of claim 1 , wherein said Calcitonin is human Calcitonin.4. The method of claim 1 , wherein said Calcitonin is synthetic Calcitonin.5. The method of claim 1 , wherein said Calcitonin is salmon Calcitonin.6. The method of claim 1 , wherein said exposing is for a time period between 4 and 36 hours.7. The method of claim 1 , wherein said exposing is done at a temperature between 17° and 37° C.8. The method of claim 1 , wherein the solution is stirred during said exposing.9. The method of claim 8 , wherein said stirring is between 50 rpm and 100 rpm.10. The method of claim 1 , further comprising implanting said treated biological tissue in a human or animal so as to create an implanted biological tissue.11. The method of claim 10 , where said implanted biological tissue is selected from the group consisting of porcine aortic valves and pericardium claim 10 , bovine pericardium claim 10 , equine pericardium claim 10 , seal aortic claim 10 , pulmonary valve and pericardium claim 10 , kangaroo aortic valve and pericardium and human seal claim 10 , porcine and dog trachea.12. The method of claim 10 , wherein said implanted biological material comprises one or more arterial conduits of human or animal origin.13. A method for treating biological tissue claim 10 , comprising a) exposing said tissue to a mixture of a fixative and Calcitonin in solution so as to create treated biological tissue; and b) implanting said treated biological tissue in a human or animal so as to create implanted ...

Подробнее
Номер записи: 45
31-03-2022 дата публикации

SINGLE CONDUIT HEART VALVE WITH UNITARY LEAFLET AND SKIRT

Номер: US20220096713A1
Автор: Humair Arnaud, Wanakoht Yutit
Принадлежит:

Embodiments herein relate to prosthetic heart valves constructed with animal tissue wherein the leaflets are unitary with the inner skirt. In an embodiment, an implantable heart valve assembly is included having a plurality of valve leaflets, an inner skirt, and a metal frame, wherein the plurality of valve leaflets and the inner skirt are formed of a continuous piece of animal tissue. In another embodiment, a method of making an implantable heart valve assembly is included, the method including placing a piece of pericardial tissue over a mold, cross-linking the pericardial tissue in place over the mold, removing the pericardial tissue from the mold, and attaching the pericardial tissue to a frame, wherein the pericardial tissue forms a seamless junction between a plurality of valve leaflets and an inner skirt. Other embodiments are also included herein. 1. An implantable heart valve assembly comprising:a plurality of valve leaflets, the plurality of valve leaflets comprising an animal tissue;an inner skirt, the inner skirt comprising an animal tissue; anda metal frame;wherein the plurality of valve leaflets and the inner skirt are formed of a continuous piece of animal tissue.2. The implantable heart valve assembly of claim 1 , wherein the animal tissue has a thickness of 100 to 500 microns.3. The implantable heart valve assembly of claim 1 , wherein the animal tissue exhibits a different degree of cross-linking in different areas of the implantable heart valve assembly.4. The implantable heart valve assembly of claim 1 , further comprising:an outer skirt, the outer skirt comprising an animal tissue.5. The implantable heart valve assembly of claim 4 , wherein the plurality of valve leaflets claim 4 , the inner skirt claim 4 , and the outer skirt are formed of a continuous piece of animal tissue.6. The implantable heart valve assembly of claim 4 , wherein the plurality of valve leaflets claim 4 , the inner skirt claim 4 , and the outer skirt are formed of a single ...

Подробнее
Номер записи: 46
12-03-2020 дата публикации

COMPOSITIONS AND METHODS FOR BIOENGINEERED TISSUES

Номер: US20200080061A1
Автор: Dinh Timothy Anh-Hieu, Hanson Arial Dawn, Reid Lola M., Sethupathy Praveen, Wauthier Eliane Lucie, YAMAUCHI Mitsuo
Принадлежит: The University of North Carolina at Chapel Hill

The present disclosure provides methods for producing bioengineered tissue along with an apparatus and other relevant compositions employed in generation thereof. 127.-. (canceled)28. A bioengineered tissue generated by introducing epithelial and mesenchymal cells into or onto a biomatrix scaffold , wherein the biomatrix scaffold comprises collagens , and wherein the epithelial and mesenchymal cells are maturational lineage partners.29. The bioengineered tissue of claim 28 , in which the epithelial and mesenchymal cells are in a seeding medium claim 28 , and the seeding medium is replaced with a differentiation medium after an initial incubation period.30. The bioengineered tissue of claim 29 , in which the differentiation medium comprises:a) a basal medium;b) lipids, insulin, transferrin, antioxidants;c) copper;d) calcium;e) one or more signaling molecules for the propagation or maintenance of epithelial cells; and/orf) one or more signaling molecules for the propagation or maintenance of mesenchymal cells.31. The bioengineered tissue of claim 29 , in which the seeding medium is serum-free or is supplemented with between about 2% to 10% fetal serum.32. The bioengineered tissue of claim 29 , in which the seeding medium comprises:a) a basal medium;b) lipids;c) insulin;d) transferrin; and/ore) antioxidants.33. The bioengineered tissue of claim 29 , in which the epithelial and mesenchymal cells in the seeding medium is incubated at 4° C. in the seeding medium for 4 to 6 hours prior to introduction into the biomatrix scaffold.34. The bioengineered tissue of claim 28 , in which the biomatrix scaffold is three-dimensional.35. The bioengineered tissue of claim 28 , in which the collagens in the biomatrix scaffold comprises (i) nascent collagens claim 28 , (ii) aggregated but not cross-linked collagen molecules claim 28 , and/or (iii) cross-linked collagens.36. The bioengineered tissue of claim 29 , in which the epithelial and mesenchymal cells in the seeding medium are ...

Подробнее
Номер записи: 47
29-03-2018 дата публикации

METHOD OF PREPARING A TISSUE SWATCH FOR A BIOPROSTHETIC DEVICE

Номер: US20180085216A1
Автор: Chalekian Aaron J., Kurane Aditee, Kutty Jaishankar
Принадлежит: St. Jude Medical, Cardiology Division, Inc.

A method of preparing a tissue swatch comprising one or more desired thicknesses for use in the manufacture of a bioprosthetic device, said method comprising sectioning a sheet of frozen tissue to produce a tissue swatch of said one or more desired thicknesses. 127-. (canceled)28. A method of manufacturing a bioprosthetic device , comprising:a. producing a tissue swatch having more than one desired thickness by sectioning a tissue sheet on a cryocutting apparatus having a straight blade and a contoured specimen disk, wherein said tissue sheet is suitable for use in the manufacture of said bioprosthetic device, and wherein said contoured specimen disk includes one of an elevated region that produces a depressed thickness of said tissue swatch or a depressed region that produces an elevated thickness of said tissue swatch;b. configuring said tissue swatch into a shape suitable for use in said bioprosthetic device; andc. incorporating said tissue swatch into said bioprosthetic device.29. The method of claim 28 , wherein said contoured specimen disk is a convex shape and said tissue swatch is of concave thickness.30. The method of claim 29 , wherein said tissue swatch of concave thickness comprises thicker peripheral regions of about 0.014 inches thick claim 29 , and a thinner inner central region of about 0.010 inches thick.31. The method of claim 28 , wherein said contoured specimen disk is a concave shape and said tissue swatch is of convex thickness.32. The method of claim 31 , wherein said tissue swatch of convex thickness comprises thinner peripheral regions of about 0.010 inches thick claim 31 , and a thicker inner central region of about 0.014 inches thick.33. The method of claim 28 , wherein said desired thickness is between 0.001 to 0.050 inches claim 28 , between 0.006 to 0.043 inches claim 28 , between 0.010 to 0.014 inches or between 0.011 to 0.013 inches.34. The method of claim 28 , wherein said tissue sheet is pericardial tissue.35. The method of claim 34 ...

Подробнее
Номер записи: 48
30-03-2017 дата публикации

FLOWABLE TISSUE PRODUCTS

Номер: US20170086962A1
Автор: Czeczuga Joshua, Hayzlett Mark, Kabaria Nimesh, Munoz Ivis
Принадлежит: LIFECELL CORPORATION

The present disclosure provides tissue fillers. The tissue fillers can include a plurality of tissue particles formed from acellular tissue matrix fragments. The tissue fillers can be used to fill tissue sites, such as voids formed after tissue resection. 1. A method of treatment , comprising:selecting a tissue site for treatment;selecting a plurality of dry flowable tissue matrix particles comprising a longest dimension between about 1 mm and 5 mm, wherein the tissue matrix particles each comprise a plurality of tissue matrix fragments having a length between 5 μm and 300 μm, and wherein the tissue matrix fragments are formed into the tissue matrix particles; andplacing the plurality of dry flowable tissue matrix particles on or in the tissue site.2. The method of claim 1 , wherein forming the fragments into particles includes joining the fragments without use of a binder or adhesive.3. The method of claim 2 , wherein the fragments are joined by convective drying.4. The method of claim 1 , wherein the tissue fragments are cross-linked to one another.5. The method of claim 1 , wherein the tissue particles each have a length between about 2 mm and 3 mm.6. The method of claim 4 , wherein the tissue fragments are cross-linked to one another using a dehydrothermal crosslinking process.7. The method of claim 1 , wherein the particles are substantially spherical.8. The method of claim 1 , wherein the particles swell when contacted with water.9. The method of claim 1 , wherein the particles form a porous structure with open channels between each of the particles that can support cellular ingrowth and vascularization.10. The method of claim 1 , wherein the tissue fragments are elongated strands of tissue matrix.11. The method of claim 1 , wherein the tissue matrix particles are dermal tissue matrix.12. The method of claim 1 , wherein the tissue matrix particles are porcine tissue matrix particles.13. The method of claim 1 , wherein the tissue matrix particles are acellular ...

Подробнее
Номер записи: 49
05-05-2022 дата публикации

Prosthetic Valves And Related Inventions

Номер: US20220133471A1
Автор: Lozonschi Lucian, Lutter Georg, Schankereli Kemal, Vidlund Robert
Принадлежит: Tendyne Holdings, Inc.

This invention relates to the design and function of a compressible valve replacement prosthesis, collared or uncollared, which can be deployed into a beating heart without extracorporeal circulation using a transcatheter delivery system. The design as discussed focuses on the deployment of a device via a minimally invasive fashion and by way of example considers a minimally invasive surgical procedure preferably utilizing the intercostal or subxyphoid space for valve introduction. In order to accomplish this, the valve is formed in such a manner that it can be compressed to fit within a delivery system and secondarily ejected from the delivery system into the annulus of a target valve such as a mitral valve or tricuspid valve.

Подробнее
Номер записи: 50
28-03-2019 дата публикации

REPLACEMENT PROSTHETIC HEART VALVES

Номер: US20190091017A1
Автор: Bakis George, Bash Assaf, Benichou Netanel, Bourang Henry, Keidar Yaron, Rowe Stanton J., Spenser Benjamin, Wood Larry L.
Принадлежит: EDWARDS LIFESCIENCES CORPORATION

A two-stage or component-based valve prosthesis that can be quickly and easily implanted during a surgical procedure is provided. The prosthetic valve comprises a support structure that is deployed at a treatment site. The prosthetic valve further comprises a valve member configured to be quickly connected to the support structure. The support structure may take the form of a stent that is expanded at the site of a native valve. If desired, the native leaflets may remain and the stent may be used to hold the native valve open. In this case, the stent may be balloon expandable and configured to resist the powerful recoil force of the native leaflets. The support structure is provided with a coupling means for attachment to the valve member, thereby fixing the position of the valve member in the body. The valve member may be a non-expandable type, or may be expandable from a compressed state to an expanded state. The system is particularly suited for rapid deployment of heart valves in a conventional open-heart surgical environment. 1. A prosthetic heart valve system comprising: an inflow end, an outflow end, and an axial axis;', 'an expandable valve member having three flexible, bioprosthetic leaflets arranged to permit blood flow from the inflow end to the outflow end of the prosthetic heart valve and to prevent blood flow from the outflow end to the inflow end thereof;', 'an expandable anchoring member including a nitinol stent having an inflow portion, an outflow portion, and, a tubular structure, the nitinol stent expandable from a delivery diameter to an implantation diameter;', 'a cover disposed on the stent; and', 'three latch assemblies, each latch assembly including a first member and a second member,', 'the first member having a first end and a second end, the first end coupled to the inflow portion of the stent and the second end extending towards the outflow end of the heart valve, the first member including a pair of parallel, spaced apart upstanding ...

Подробнее
Номер записи: 51
26-03-2020 дата публикации

SIDE-DELIVERED TRANSCATHETER HEART VALVE REPLACEMENT

Номер: US20200093589A1
Автор: Christianson Mark, Saikrishnan Neelakantan, Vidlund Robert
Принадлежит:

The invention relates to a transcatheter heart valve replacement (A61F2/2412), and in particular to a side delivered large diameter, low profile transcatheter prosthetic valve having a compressible tubular frame having a side wall and a central axial lumen, said tubular frame having a height of 8-20 mm and a diameter of 40-80 mm, an atrial sealing cuff, a subannular anchoring component, and aa flow control component comprising a leaflet structure, wherein the valve is side-delivered longitudinally to a mitral valve annulus or tricuspid valve annulus of a patient using a 22-34 Fr delivery catheter. 1. A side-delivered transcatheter prosthetic valve comprising:a compressible tubular frame having a side wall and a central axial lumen, said tubular frame having a height of 8-20 mm and a diameter of 40-80 mm,an atrial sealing cuff attached to a top edge of the side wall,a subannular anchoring component attached to the tubular frame, said subannular anchoring component selected from one or more of the group consisting of a lower tension arm extending from a distal side of the tubular frame, a proximal anchoring tab extending from a proximal side of the tubular frame, a ventricular sealing collar attached to a bottom edge of the side wall, and at least one tissue anchor to connect the tubular frame to native tissue, anda flow control component comprising a leaflet structure having three leaflets of pericardial material sewn to a leaflet frame to form a rounded cylinder mounted within the lumen of the tubular frame and configured to permit blood flow in a first direction through an inflow end of the valve and block blood flow in a second direction, opposite the first direction, through an outflow end of the valve,wherein the valve is compressible to a compressed configuration for introduction into the body using a delivery catheter for implanting at a mitral valve annulus or tricuspid valve annulus of a patient, said delivery catheter having an internal diameter from 22 Fr ...

Подробнее
Номер записи: 52
12-04-2018 дата публикации

BIOCOMPATIBLE CONTAINMENT MEMBER FOR BONE AUGMENTATION SURGERY MADE OF PROCESSED NATURAL MEMBRANE FROM AN ANIMAL DONOR

Номер: US20180099073A1
Автор: Cheung David
Принадлежит: Osseous Technologies of America

A surgically implantable containment member for maintaining a bone augmentation material in a desired location and/or configuration following implantation in a human or other mammalian patient, in which the containment member is made of a natural membrane, such as pericardium, isolated from an animal donor and processed to avoid inflammation or tissue rejection, and a method of bone augmentation using such a containment member. In a particularly preferred embodiment, the containment member has a window which rapidly dissipates upon exposure to bodily fluids after implantation to expose bone augmentation material contained within the containment member to an adjacent bone to be augmented. 1. A surgically implantable containment member for maintaining a bone augmentation material in a desired location and/or configuration following implantation in a mammalian patient , wherein said containment member is comprised of a natural membrane isolated from an animal donor and processed to avoid inflammation or tissue rejection , wherein said containment member comprises an arcuate sheet with parallel leg sections joined at one end by a closed curved section and further comprising a flap which serves as a point of attachment for fixing the containment member in a desired implanted location.2. A containment member according to claim 1 , wherein following the processing said containment member retains the natural membrane structure of the isolated natural membrane.3. A containment member according to claim 1 , wherein said isolated natural membrane is pericardial membrane.4. a containment member according to claim 1 , wherein said containment member has the form of a cylindrical capsule formed of two sections each of which has a closed end and an open end with the open end of one section sized for mating insertion into the open end of the other section to form a closed containment structure.5. A containment member according to claim 4 , wherein at least one section comprises a ...

Подробнее
Номер записи: 53
08-04-2021 дата публикации

Methods for stabilizing a bioprosthetic tissue by chemical modification of antigenic carbohydrates

Номер: US20210100931A1
Автор: Jeffrey S. Dove, Tara J. Tod
Принадлежит: Edwards Lifesciences Corp

Methods are provided herein for modifying antigenic carbohydrate epitopes within a xenographic bioprosthetic tissue by oxidation of vicinal diols to form aldehydes or acids and subsequence reductive amination of aldehydes to form stable secondary amines, or amidation or esterification of acids to form stable amides or esters. Advantageously, methods provided herein mitigate the antigenicity of the bioprosthetic tissue while leaving the overall tissue structure substantially undisturbed, and thereby enhance the durability, safety and performance of the bioprosthetic implant.

Подробнее
Номер записи: 54
09-06-2022 дата публикации

A process for prevention of degradation and degeneration of tissue used in bioprosthesis

Номер: US20220176018A1
Автор: Amirhamzah Mahmadiqbal SHAIKH, Deveshkumar Mahendralal KOTHWALA, Pramod Kumar Minocha
Принадлежит: Meril Life Sciences PVT LTD

There is disclosed a process for treatment to avert enzymatic degradation and tissue degeneration of bovine pericardium tissue, used for making bioprosthesis for implant application, comprising the steps of collecting and harvesting raw bovine pericardial tissue; chemically cross-linking the rinsed tissue to generate fixed tissue; laser cutting said fixed tissue to produce tissue leaflet; chemically treating said tissue leaflet with AAS; chemically sterilising and storing the fixed bovine pericardium tissue to maintain the structural integrity and characteristics; and wherein all the above steps are carried out in a low-oxygen and controlled temperature environment.

Подробнее
Номер записи: 55
30-04-2015 дата публикации

SYSTEM AND METHOD TO LIMIT CEREBRAL ISCHEMIA

Номер: US20150119977A1
Автор: Berguer Ramon, Parodi Juan
Принадлежит:

A system to limit cerebral ischemia occurring as a consequence of aortic valve replacement includes an aortic valve having proximal and distal ends, a sleeve having proximal and distal ends, the proximal end of the sleeve disposed at the distal end of the aortic valve, and a filter attached to the distal end of the sleeve to receive blood and particles passing from the proximal end of the sleeve to the distal end of the sleeve and to separate the particles from the blood. A related method includes introducing a system into a heart of a patient, the system comprising an aortic valve having proximal and distal ends and a sleeve having a proximal end disposed at the distal end of the valve, implanting the valve in an aortic valve annulus, and filtering blood that has passed through the valve into the sleeve. 1. A system to limit cerebral ischemia occurring as a consequence of aortic valve replacement , the system comprising:an aortic valve having a proximal end and a distal end;a sleeve having a proximal end and a distal end, the proximal end of the sleeve disposed at the distal end of the aortic valve; anda filter attached to the distal end of the sleeve to receive blood and particles passing from the proximal end of the sleeve to the distal end of the sleeve and to separate the particles from the blood.2. The system according to claim 1 , further comprising a cannula connected to the filter to return blood from the filter to the patient.3. The system according to claim 1 , further comprising a removable fastener that attaches the proximal end of the sleeve to the distal end of the valve.4. The system according to claim 3 , wherein the removable fastener comprises at least one suture that attaches the proximal end of the sleeve to the distal end of the valve.5. The system according to claim 4 , wherein the removable fastener comprises at least one flexible release mechanism having a proximal end attached to the at least one suture and a distal end.6. The system ...

Подробнее
Номер записи: 56
04-05-2017 дата публикации

LEAFLET FOR LOW GRADIENT PROSTHETIC HEART VALVE

Номер: US20170119523A1
Автор: Cao Hengchu, Sun Wei
Принадлежит:

A low pressure gradient prosthetic heart valve for implant in a human. The valve includes a support frame with undulating inflow cusps and outflow commissure posts to which flexible leaflets attach and coapt in a flow area. The commissure posts angle outward in a neutral state to widen the outflow orifice area. Also, the leaflets are designed to fit within the support frame and expand outward in a valve open state without creating a shelf or belly that would restrict flow. 1. A leaflet for a low pressure gradient prosthetic heart valve , comprising:a flexible leaflet having an arcuate cusp edge opposite a free edge and opposed attachment tabs therebetween, the leaflet having a central area subject to stress when secured within a surrounding heart valve support frame, the leaflet being symmetric about a central midplane and the arcuate cusp edge being defined by a complex curve of multiple radii, the complex curve having its smallest radius on the central midplane that gradually increases on both sides away from the central plane, reaches a maximum at about 45° angle from the central axis, and then gradually decreases to two corners where the two ends of the arcuate cusp edge meet the attachment tabs.2. The leaflet of claim 1 , wherein the free edge diverges above a straight line drawn between the side tabs to form a supplemental strip of leaflet material that gradually widens as it progresses inward from the tabs until it forms a plateau for a majority of its length claim 1 , and then rapidly widens in converging curves that lead to an apex on the vertical midplane.3. The leaflet of claim 1 , wherein the free edge diverges above a straight line drawn between the side tabs to form a supplemental strip of leaflet material shaped generally as a triangle with an apex on the vertical midplane.4. The leaflet of claim 1 , wherein the leaflet is cut from bovine pericardium.5. The leaflet of claim 1 , wherein a thickness of the leaflet is between 0.014-0.025 inches (0.36-0. ...

Подробнее
Номер записи: 57
04-05-2017 дата публикации

REPLACEMENT PROSTHETIC HEART VALVES

Номер: US20170119525A1
Автор: Bakis George, Bash Assaf, Benichou Netanel, Bourang Henry, Keidar Yaron, Rowe Stanton J., Spenser Benjamin, Wood Larry L.
Принадлежит:

A two-stage or component-based valve prosthesis that can be quickly and easily implanted during a surgical procedure is provided. The prosthetic valve comprises a support structure that is deployed at a treatment site. The prosthetic valve further comprises a valve member configured to be quickly connected to the support structure. The support structure may take the form of a stent that is expanded at the site of a native valve. If desired, the native leaflets may remain and the stent may be used to hold the native valve open. In this case, the stent may be balloon expandable and configured to resist the powerful recoil force of the native leaflets. The support structure is provided with a coupling means for attachment to the valve member, thereby fixing the position of the valve member in the body. The valve member may be a non-expandable type, or may be expandable from a compressed state to an expanded state. The system is particularly suited for rapid deployment of heart valves in a conventional open-heart surgical environment. 1. A replacement prosthetic heart valve , comprising:an expandable anchoring member sized to contact a heart valve annulus in an expanded state and defining a lumen having an inner diameter, the anchoring member having a circular cross-section and a length such that the anchoring member may be expanded within a native valve annulus to the push aside valvular leaflets of the native valve; anda one-way valve member comprising a non-expandable/non-collapsible support frame and defining an exterior dimension sized to fit within the lumen of the anchoring member, the valve member and anchoring member being configured to engage each other and hold the valve member within the lumen.2. The heart valve of claim 1 , wherein the anchoring member comprises a stent having a wider outflow end than an inflow end claim 1 , and wherein the valve member comprises a base ring surrounding an inflow end thereof claim 1 , the base ring being sized to fit within ...

Подробнее
Номер записи: 58
07-05-2015 дата публикации

METHOD FOR REPLACING MITRAL VALVE

Номер: US20150127096A1
Автор: Chau Mark, Nguyen Son V., Rowe Stanton J.
Принадлежит: EDWARDS LIFESCIENCES CORPORATION

A method of implanting a prosthetic mitral valve assembly using a transapical procedure is disclosed. An incision is formed in the chest in the apex of the patient's heart. A delivery catheter containing the prosthetic mitral valve assembly is advanced over a guidewire into the patient's heart. The prosthetic mitral valve assembly is deployed from the delivery catheter into the native mitral valve. The prosthetic mitral valve assembly comprises a stent having a lower portion for placement between the leaflets of a native mitral valve and an upper portion having a flared end for placement above the annulus. The prosthetic mitral valve includes a valve portion having leaflets formed of pericardial tissue. A plurality of upwardly bent prongs are provided along an outer surface of the stent for preventing upward migration of the prosthetic mitral valve assembly after deployment. 1. A prosthetic mitral valve assembly , comprising:a radially-expandable stent including a lower portion sized to held between leaflets of a native mitral valve and an upper portion having a flared end, the upper portion sized for deployment within the annulus of the mitral valve with a pressure fit, the flared end configured to extend above the annulus, the stent comprising a tubular portion, wherein the tubular portion of the stent tapers from the upper portion to the lower portion with a reduced diameter, the stent having a substantially D-shape cross-section for conforming to the native mitral valve, the D-shape cross-section providing a substantially straight portion configured to extend along an anterior side of the native mitral valve and a substantially curved portion configured to extend along a posterior side of the native mitral valve; anda valve portion formed of pericardial tissue and mounted within an interior portion of the stent, the valve portion having leaflets for occluding blood flow in one direction and replacing the function of the native mitral valve.2. The prosthetic ...

Подробнее
Номер записи: 59
25-04-2019 дата публикации

Extracellular matrix sheet structures

Номер: US20190117836A1
Автор: Robert G. Matheny
Принадлежит: Aziyo Med LLC

An implantable medical product and method of use for substantially reducing or eliminating harsh biological responses associated with conventionally implanted medical devices, including inflammation, infection and thrombogenesis, when implanted in in a body of a warm blooded mammal. The bioremodelable pouch structure is configured and sized to receive, encase and retain an electrical medical device therein and to allow such device to be inserted into the internal region or cavity of the pouch structure; with the pouch structure formed from either: (a) first and second sheets, or (b) a single sheet having first and second sheet portions. After receiving the electrical device, the edges around the opening are closed by suturing or stapling. The medical device encased by the bioremodelable pouch structure effectively improves biological functions by promoting tissue regeneration, modulated healing of adjacent tissue or growth of new tissue when implanted in the body of the mammal.

Подробнее
Номер записи: 60
25-04-2019 дата публикации

METHOD OF PROCESSING BIOLOGICAL TISSUE

Номер: US20190117841A1
Автор: Ashworth Paul E.
Принадлежит: St. Jude Medical, Cardiology Division, Inc.

Methods of preparing biological tissue for bioprosthetic valves include providing fresh biological tissue; treating the tissue with an aqueous cellulose solution for a time sufficient to allow the fluid in the tissue to be replaced by the aqueous cellulose solution; and cross-linking the tissue, wherein the treating step is performed prior to, during, after, or both prior to and after the cross-linking step. The methods may include storing the cellulose-treated and cross-linked tissue in an aqueous solution; or drying the cellulose-treated and cross-linked tissue by a vacuum-drying or lyophilization process, and storing the dried tissue in a dry, ambient environment. The treated tissue may be in the form of a tissue component for a bioprosthetic valve, a valve assembly for a bioprosthetic valve or a fully assembled bioprosthetic valve incorporating the tissue. 1. A method of processing tissue , comprising:providing fresh biological tissue;treating the tissue with an aqueous cellulose solution for a time sufficient to allow fluid in the tissue to be replaced by the aqueous cellulose solution; andcross-linking the tissue,wherein the treating step is performed prior to, during, after, or both prior to and after the cross-linking step.2. The method of claim 1 , further comprising storing the cellulose-treated cross-linked tissue in an aqueous solution.3. (canceled)4. The method of claim 1 , further comprisingdrying the cellulose-treated cross-linked tissue by a vacuum-drying or lyophilization process to form dried tissue; andstoring the dried tissue in a dry, ambient environment.5. (canceled)6. The method of claim 4 , wherein the vacuum-drying process uses a vacuum of no more than 200 mTorr.7. The method of claim 4 , wherein the drying step is performed for at least 4 hours.8. The method of claim 4 , further comprising placing the dried tissue in a package and sealing the package.9. The method of claim 8 , further comprising sterilizing the package after the sealing ...

Подробнее
Номер записи: 61
11-05-2017 дата публикации

ORGANOIDS COMPRISING DECELLULARIZED AND REPOPULATED PLACENTAL VASCULAR SCAFFOLD

Номер: US20170128625A1
Автор: Bhatia Mohit B., Hariri Robert J., Hofgartner Wolfgang, Wang Jia-Lun, Ye Qian
Принадлежит: Anthrogenesis Corporation

Provided herein are organoids comprising decellularized placental vascular scaffold comprising, or consisting of, a decellularized placental vascular scaffold, and methods of making and using the same. 1. An organoid , comprising one or more types of cells , and comprising decellularized placental vascular scaffold , wherein said organoid performs at least one function of an organ , or a tissue from an organ , wherein said at least one function of an organ or tissue from an organ is production of a protein , growth factor , cytokine , interleukin , or small molecule characteristic of at least one cell type from said organ or tissue; and wherein said decellularized placental vascular scaffold comprises substantially intact placental vasculature matrix.25-. (canceled)6. The organoid of claim 1 , additionally comprising a synthetic matrix.7. The organoid of claim 6 , wherein said synthetic matrix stabilizes the three-dimensional structure of said placental vascular scaffold.8. The organoid of claim 6 , wherein said synthetic matrix comprises a polymer or a thermoplastic.9. The organoid of claim 6 , wherein said synthetic matrix is a polymer or a thermoplastic.10. The organoid of claim 8 , wherein said thermoplastic is polycaprolactone claim 8 , polylactic acid claim 8 , polybutylene terephthalate claim 8 , polyethylene terephthalate claim 8 , polyethylene claim 8 , polyester claim 8 , polyvinyl acetate claim 8 , or polyvinyl chloride.11. The organoid of claim 8 , wherein said polymer is polyvinylidine chloride claim 8 , poly(o-carboxyphenoxy)-p-xylene) (poly(o-CPX)) claim 8 , poly(lactide-anhydride) (PLAA) claim 8 , n-isopropyl acrylamide claim 8 , acrylamide claim 8 , pent erythritol diacrylate claim 8 , polymethyl acrylate claim 8 , carboxymethylcellulose claim 8 , or poly(lactic-co-glycolic acid) (PLGA).12. The organoid of claim 8 , wherein said polymer is polyacrylamide.13. The organoid of claim 1 , wherein said one or more types of cells comprise natural killer ( ...

Подробнее
Номер записи: 62
01-09-2022 дата публикации

VALVE TRANSLOCATION DEVICE AND METHOD FOR THE TREATMENT OF FUNCTIONAL VALVE REGURGITATION

Номер: US20220273431A1
Автор: Gammie James, PASRIJA Chetan, QUINN Rachael
Принадлежит:

The present invention provides devices for treating functional mitral regurgitation and methods of use thereof. The devices translocate a subject's mitral valve in an apical direction. The devices thereby treat mitral regurgitation while preserving a subject's original mitral valve and chordae tendinae. 1. An apparatus comprising:a ring-shaped body having an annulus portion and a leaflet portion axially spaced from the annulus portion,the annulus portion having an annulus end having a perimeter and being configured to be attached to an annulus of a native heart valve from which a leaflet of the native heart valve has been separated,the leaflet portion having a leaflet end having a perimeter equal to or larger than the annulus portion perimeter and being configured to be attached to the native heart valve leaflet and thereby to connect the native heart valve leaflet to the native heart valve annulus.2. The apparatus of claim 1 , wherein the leaflet portion of the ring-shaped body includes a pleat having an expandable portion extending to the leaflet end of the ring-shaped body to define in part the perimeter of the leaflet end and a fixed portion spaced from the leaflet end claim 1 , the expandable portion of the pleat being configured to be attached to the native heart valve leaflet.3. The apparatus of claim 2 , wherein:the pleat is a first pleat,the expandable portion of the first pleat is configured to be attached to the leaflet,the leaflet portion of the ring-shaped body includes a second pleat having an expandable portion extending to the leaflet end of the ring-shaped body further to define in part the perimeter of the leaflet end and a fixed portion spaced from the leaflet end, the expandable portion of the second pleat being configured to be attached to the leaflet.4. The apparatus of claim 1 , wherein:the leaflet end of the ring-shaped body has a first circumferential portion having a thickness and a second circumferential portion have a thickness different ...

Подробнее
Номер записи: 63
02-05-2019 дата публикации

PREVENTING BLOOD CLOT FORMATION, CALCIFICATION AND/OR PLAQUE FORMATION ON BLOOD CONTACT SURFACE(S)

Номер: US20190125932A1
Автор: Donofrio Jeff, Leonhardt Howard J.
Принадлежит:

Described is a device for preventing thrombosis formation on surfaces of a blood contact device. The device may first non-invasively scan the blood contact device and determines the highest risk thrombosis points. The device then, preferably starting with the highest risk location, delivers a succession of harmonic vibration signals or electromagnetic signals non-invasively so as to prevent clot formation at each stagnation high risk point of the blood contact device (e.g., harmonic resonance). This resonant vibration calibration tuning information is stored in an associated microprocessor. The signals are then delivered, based upon the stored information, in a loop from the signal generator, usually on a belt outside the patient, to each stagnation point in sequence from highest risk of thrombosis to lowest; again and again repeated. By delivering such energy to the blood contact device stagnation points, initiation of thrombosis formation is prevented, thus preventing the accumulation of thrombosis to a dangerous risk level for stroke, pulmonary embolism, and/or other blood clot induced ailments. This device may be used to prevent and/or treat blood clot, plaque, and/or calcification formation on any blood contact surfaces including living surfaces such as heart valves. 1. A device comprising:a sensor that detects harmonic frequency and/or electromagnetic energy and recognizes resonance and/or ionic charge on a blood contact surface,a microprocessor for analyzing data from the sensor, andan emitter of sound, ultrasound, and/or electromagnetic energy associated with said microprocessor that can create and focus a specific sound, ultrasound, and/or electromagnetic energy onto the blood contact surface.2. The device of claim 1 , wherein the sensor of the device detects harmonic frequency claim 1 , and the device first reads and then the microprocessor custom tunes in the appropriate harmonic frequency to prevent the beginning of blood clot formation claim 1 , ...

Подробнее
Номер записи: 64
01-09-2022 дата публикации

BIOLOGICAL VALVE FOR VENOUS INSUFFICIENCY

Номер: US20220273848A1
Автор: JAFFE NORMAN
Принадлежит: enVVeno Medical Corporation

A bioprosthetic valve for repairing a deep venous insufficiency in a subject includes a single leaflet from a xenogeneic heart valve attached at natural margins of attachment to a patch of valve wall tissue. The patch may extend axially above and below the leaflet and circumferentially on either side of the leaflet to provide a region for attaching the patch to a fenestration in a host vein. A bioprosthetic valve may be manufactured by excising a portion of a xenogeneic heart valve including a single leaflet and contiguous wall tissue, and may further comprise shaving off excess leaflet tissue from adjacent leaflets. A method of replacing a malfunctioning venous valve in a subject includes providing a bioprosthetic valve as described above and inserting it to the host vein. 1. A method of manufacturing a replacement monocusp venous valve for a host vein of a subject , comprising:modifying a porcine aortic xenogenic heart valve to excise leaflets from the xenogenic heart valve except for an aortic noncoronary leaflet and including a natural sinus of the xenogenic heart valve so that the natural sinus provides a spatial buffer between a free edge of the noncoronary leaflet and a valve wall that facilitates opening and closing of the noncoronary leaflet based on flow pressure through the valve; andincluding natural margins of attachment with the noncoronary leaflet.2. The method of claim 1 , further comprising the step of attaching a patch to said monocusp venous valve to form a monocusp venous valve that is generally rectangular in shape.3. The method of claim 2 , wherein said patch is selected from porcine heart valve tissue.4. The method of claim 1 , further comprises the step of subjecting said monocusp venous valve to crosslinking treatment.5. The method of claim 2 , further comprises the step of subjecting said monocusp venous valve to crosslinking treatment.6. The method of claim 4 , wherein the crosslinking treatment includes using a glutaraldehyde solution.7. ...

Подробнее
Номер записи: 65
17-05-2018 дата публикации

HEART VALVE BIOPROSTHESIS AND MANUFACTURING METHOD THEREOF

Номер: US20180133002A1
Автор: YI Dinghua, ZHANG Hao, ZHAO Yimin
Принадлежит:

A heart valve bioprosthesis () and a manufacturing method thereof are provided. The heart valve bioprosthesis () comprises: a support frame (), valve leaflets () and a valve auxiliary structure. The valve leaflets () are connected to the valve auxiliary structure, the valve auxiliary structure is connected to the support frame (). Both the valve leaflets () and the valve auxiliary structure are made of biological tissues. The support frame () is formed as a single component with an elastic material, and the valve auxiliary structure is preset with suturing marks. The heart valve bioprosthesis improves the biocompatibility with the human body, reduces the total height of the valve, shortens the suturing time, and decreases the possibility of thrombus or bacterial attachment thereto. In addition, the heart valve bioprosthesis is made by a simple process, exhibit excellent compliance with the cardiac tissue, and has a prolonged service life. 126-. (canceled)27. A heart valve bioprosthesis comprising a support frame , valve leaflets and a valve auxiliary structure , said valve leaflets are connected to the valve auxiliary structure , and said valve auxiliary structure is connected to the support frame; whereinsaid valve leaflets are made from animal pericardium or porcine aortic valve leaflets;said valve auxiliary structure is made from animal pericardium and comprises a suture ring and a covering material, said covering material comprising an inner covering and an outer covering; wherein said support frame is placed within a space formed between the inner covering and the outer covering;said valve leaflets, said suture ring and said covering material are preset with suturing marks so that the distance between two adjacent suturing marks is 0.5-3 mm; wherein suturing along the suturing marks produces said heart valve bioprosthesis;said support frame is made of an elastic material; andsaid suture ring is for suturing to cardiac tissues.28. The heart valve bioprosthesis ...

Подробнее
Номер записи: 66
17-05-2018 дата публикации

COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING TISSUE INJURY AND DISEASE

Номер: US20180133371A1
Автор: MATTERN Ralph-Heiko, Ohashi Kevin L., Peterson Dale R., WILSON Corey
Принадлежит:

The present invention provides novel compositions comprising multipotent cells or microvascular tissue, wherein the cells or tissue has been sterilized and/or treated to inactivated viruses, and related methods of using these compositions to treat or prevent tissue injury or disease in an allogeneic subject. 1. A composition comprising isolated multipotent cells wherein the composition is sterilized , has angiogenic or anti-inflammatory activity greater than saline alone , and less than or equal to 50% of the cells are viable.2. The composition of claim 1 , wherein 10% of the cells present in said composition are viable.3. The composition of claim 1 , wherein substantially none of the cells present in said composition are viable.4. The composition of claim 1 , wherein at least 1% of said cells exclude trypan blue.5. The composition of claim 1 , wherein the cells have been sterilized by irradiation greater than 0.5 Mrad.6. The composition of wherein the multipotent cells have been isolated from a tissue selected from the group consisting of bone marrow claim 1 , adipose tissue claim 1 , and muscle.7. The composition of claim 1 , wherein said composition is dried claim 1 , lyophilized or cryopreserved.8. The composition of claim 1 , wherein said composition retains measurable angiogenic or anti-inflammatory activity when stored at approximately room temperature for at least one month.9. The composition of wherein the composition further comprises an implantable scaffold or matrix.10. The composition of wherein the composition is formulated for intravenous administration.11. The composition of wherein the cells are obtained from a mammalian donor claim 1 , optionally a human.12. The composition of wherein the cells comprise stem cells or progenitor cells.13. A kit comprising isolated multipotent cells in a hermetically sealed container wherein the cells have been lyophilized and sterilized by irradiation and wherein the cells have one or more of angiogenic claim 1 , ...

Подробнее
Номер записи: 67
09-05-2019 дата публикации

METHOD OF REPLACING MITRAL VALVE

Номер: US20190133761A1
Автор: Chau Mark, Nguyen Son V., Rowe Stanton J.
Принадлежит:

A deficient native mitral valve is treated by implanting a prosthetic mitral valve assembly valve in a patient's heart. The prosthetic mitral valve assembly includes a stent having a flared upper portion, an intermediate portion, and a lower portion. The diameter at the inflow end of the stent is larger than at the outflow end. The prosthetic mitral valve assembly also includes a valve portion formed with pericardial tissue leaflets. A tether has a first end attached to the stent and a second end attached to an anchor. The tether extends through a wall of the left ventricle and the tissue anchor is placed outside the left ventricle. After implantation, the flared upper portion resists movement in the downstream direction and the tether resists movement in the upstream direction for securing the prosthetic mitral valve assembly in the native mitral valve. 1. A method for treating a deficient native mitral valve , comprising:inserting a prosthetic mitral valve assembly valve into a patient's heart, the prosthetic mitral valve assembly comprising a radially-expandable stent including a flared upper portion terminating at an inlet end, a lower portion terminating at an outlet end, and an intermediate portion between the upper and lower portions, wherein the outlet end has an outlet diameter that is less than an inlet diameter at the inlet end, wherein the inlet end is defined by a circumferentially extending row of struts that extends continuously around a circumference of the flared upper portion;wherein the prosthetic mitral valve assembly further comprises a valve portion comprising pericardial tissue leaflets positioned within an interior portion of the stent, a tissue anchor and a tether having a first end portion and a second end portion, the first end portion coupled to the stent and the second end portion coupled to the tissue anchor;radially expanding the stent from a radially compressed state to a radially expanded state within the native mitral valve such ...

Подробнее
Номер записи: 68
08-09-2022 дата публикации

IMMUNOCOMPATIBLE TISSUE SCAFFOLD AND METHODS OF FORMING THE SAME

Номер: US20220280697A1
Автор: Bozso Sabin J., Nagendran Jayan, Nagendran Jeevan
Принадлежит:

A method of forming an immunocompatible scaffold for a recipient. A decellularized tissue matrix is contacted in vitro with eukaryotic cells immunocompatible to the recipient to cover an exterior surface of the decellularized tissue matrix to form the immunocompatible scaffold. The decellularized tissue is formed from tissue xenogenic to the recipient. The decellularized tissue matrix may be contacted with alpha-galactosidase prior to recellularizing the decellularized tissue matrix. This process may be completed in a manner of days, rather than weeks. The immunocompatible scaffold may be fixed with a fixing agent such as glutaraldehyde, forming a shelf stable product. 1. A method of forming an immunocompatible scaffold for a recipient , comprising contacting a decellularized tissue matrix in vitro with eukaryotic cells immunocompatible to the recipient to cover an exterior surface of the decellularized tissue matrix to form the immunocompatible scaffold , the decellularized tissue formed from tissue xenogenic to the recipient.2. The method of in which the eukaryotic cells further comprise multipotent cells.3. The method of in which the multipotent cells further comprise mesenchymal stem cells.4. The method of in which the decellularized tissue matrix further comprises a decellularized extracellular matrix.5. The method of in which the eukaryotic cells immunocompatible to the recipient further comprise cells homologous or autologous to the recipient.6. The method of further comprising contacting the decellularized tissue matrix with alpha-galactosidase prior to recellularizing the decellularized tissue matrix.7. The method of further comprising fixing the xenogenic scaffold with a fixing agent.8. The method of in which the fixing agent is glutaraldehyde.9. The method of in which the decellularized tissue matrix further comprises heart valve tissue.10. The method of in which the recipient is human and the tissue is mammalian tissue.11. The method of in which the ...

Подробнее
Номер записи: 69
09-05-2019 дата публикации

MEMBRANOUS TISSUE WITH EVENLY SPACED ELEVATED PROJECTIONS ON ONE SIDE AND CONCAVE DEPRESSIONS ON THE OTHER SIDE METHOD AND USE

Номер: US20190134268A1
Автор: Malinin Theodore I.
Принадлежит:

The present invention discloses the method of preparation and use of soft tissue membranous structures into slip resistant membranes with regularly spaced surface projections on one side and concave depressions on the other side with perforations or without perforations which enhance vascular ingrowth and tissue incorporation. 1. A method of making smooth two-sided wetted or non-dried biological membranes into three-dimensional membrane structures with regularly or irregularly spaced surface concave depressions on an at least first side and projections on at least the opposite second side , the method comprising the steps of:acquiring a smooth two sided wetted or non-dried membrane for drying;placing the smooth wetted or non-dried membrane on a support surface of a perforated plate, the perforated plate having a plurality of holes or depressions on the support surface of the plate for forming depressions on a first side of the membrane and projections on an opposite second side adjacent the support surface; anddrying the smooth wetted or non-dried membrane on the perforated plate wherein the smooth wetted or non-dried membrane locally sags or sinks into the perforations forming depressions on the first side and corresponding projections on the opposite second side of the membrane converting the membrane into a three-dimensional structure when dried.2. The method of further comprises the step of perforating at least one or more of the surface projections on the second side and concave depressions on the first side in the membranes to form open perforations at an end of the at least one or more projections of the three-dimensional membrane structure.3. The method of wherein the smooth two-sided wetted or non-dried membrane is freeze-dried on perforated plates and retained in place by compressing the membrane with solid plates or under vacuum.4. The method of wherein either prior to drying or post drying the three-dimensional structure has projections formed on the ...

Подробнее
Номер записи: 70
09-05-2019 дата публикации

ENGINEERING MULTILEVEL CELL SHEET-DERIVED BLOOD VESSELS

Номер: US20190134274A1
Автор: von Bornstaedt Daniel, Wang Hanjay, Woo Y. Joseph
Принадлежит:

Engineered multilevel cell sheet-derived blood vessels and methods of preparing and using them are disclosed. Blood vessels are generated by wrapping cell sheets around a rod-like device, such as an angiocath needle, to form a tube, which is stabilized with a cyanoacrylate membrane or fibrin glue followed by endothelialization. Such engineered blood vessels can be implanted in tissue and used in vascular surgery as vascular bypass or interposition grafts as well as for vascularization and perfusion of tissue or organs prior to transplant. 1. A method of making a tissue-engineered blood vessel comprising:a) culturing fibroblasts and smooth muscle cells to form one or more confluent cell sheets;b) wrapping said one or more cell sheets around a rod-like device to form a tube;c) stabilizing the tube formed from the cell sheets with a cyanoacrylate membrane or fibrin glue;d) endothelialization of the tube formed from the cell sheets by culturing with endothelial cells; ande) removing the rod-like device to form the tissue-engineered blood vessel.2. The method of claim 1 , wherein the fibroblasts and smooth muscle cells are from a human subject.3. The method of claim 1 , wherein the endothelial cells are human umbilical vein endothelial cells.4. The method of claim 1 , wherein the diameter of the rod-like device is less than or equal to 1 mm.5. The method of claim 1 , wherein the rod-like device is a mandrel or needle.6. The method of claim 5 , wherein the needle is an angiocath needle.7. The method of claim 5 , wherein the needle has a gauge of at least 11 claim 5 , at least 16 claim 5 , at least 18 claim 5 , at least 20 claim 5 , at least 22 claim 5 , or at least 22.5.8. The method of claim 7 , wherein the needle has a gauge ranging from 11 to 24.9. The method of claim 8 , wherein the needle has a gauge of 22.5.10. The method of claim 1 , wherein at least 4 claim 1 , 5 claim 1 , 6 claim 1 , 7 claim 1 , 8 claim 1 , 9 claim 1 , 10 claim 1 , 11 claim 1 , or 12 cell sheets ...

Подробнее
Номер записи: 71
10-06-2021 дата публикации

Adaptable Prosthetic Tissue Valves

Номер: US20210169644A1
Автор: Matheny Robert G
Принадлежит:

Prosthetic valves that include conical shaped base valve members having an annular engagement end, a closed distal end region that restricts fluid flow therethrough, and a plurality of elongated ribbon members, which transition from an open fluid flow configuration to a closed fluid flow configuration in response to expansion and contraction of the base valve member, and a support structure that is configured and adapted to exert retaining forces on the annular engagement ends of the base valve members, whereby the support structure (i) conforms to the shape of the annular engagement ends of the base valve members, (ii) securely positions the annular engagement ends of the base valve members adjacent to and, thereby, in contact with a valve annulus, whereby the annular engagement ends of the base valve members conform to the shape of the valve annulus, and (iii) the annular engagement ends of the base valve members adapt to at least one fluctuation in the configuration and/or dimension of the valve annulus, whereby the annular engagement ends of the base valve members maintain contact therewith. 1. An adaptable prosthetic valve for modulating fluid flow through an atrioventricular (AV) valve annulus region during cardiac cycles of a heart , said AV valve annulus region comprising a plurality of AV valve annulus configurations and a plurality of AV valve annulus dimensions , said prosthetic valve comprising:a base valve member and an internal support structure, said base valve member comprising a seamless sheet member,said base valve member comprising mammalian-based tissue from a mammalian tissue source,said base valve member comprising an internal lumen adapted to transmit fluid flow therethrough, a proximal annular engagement end and a distal end,said proximal annular engagement end being configured to engage said AV valve annulus region,said proximal annular engagement end being further configured and adapted to transition from a first proximal annular engagement ...

Подробнее
Номер записи: 72
10-06-2021 дата публикации

Reinforced Prosthetic Valves

Номер: US20210169647A1
Автор: Matheny Robert G.
Принадлежит:

A prosthetic valve comprising a conical shaped sheet structure and a support structure, the sheet structure having a closed distal end and a plurality of elongated ribbon members that are positioned proximate each other in a joined relationship, whereby the ribbon members form a plurality of fluid flow modulating regions that close when fluid flow through the valve exhibits a negative flow pressure and open when fluid flow through the valve exhibits a positive flow pressure, the support structure having at least one elongated cardiovascular structure engagement member that is associated with one of the ribbon members and adapted to engage a cardiovascular structure. 1. A prosthetic valve for modulating fluid flow through an atrioventricular (AV) valve annulus region during cardiac cycles of a heart , said fluid flow exhibiting a plurality of fluid pressures during said cardiac cycles , said prosthetic valve comprising:a continuous conical shaped biological tissue member and a support structure,said biological tissue member comprising an adaptive tissue regeneration system adapted to induce modulated healing of cardiovascular tissue of said AV valve annulus region concomitantly with stress-induced hypertrophy of said biological tissue member when said biological tissue member is subjected to cardiac cycle induced physical stimuli,said modulated healing of said cardiovascular tissue comprising inflammation modulation of said cardiovascular tissue and induced neovascularization, remodeling of said cardiovascular tissue and regeneration of new cardiovascular tissue and tissue structures with site-specific structural and functional properties,said stress-induced hypertrophy of said biological tissue member comprising adaptive remodeling of said biological tissue member, wherein said biological tissue member forms functioning valve structures that are similar to native valve structures,said adaptive tissue regeneration system of said biological tissue member comprising a ...

Подробнее
Номер записи: 73
24-05-2018 дата публикации

METHODS FOR TREATING RESTENOSIS USING ANNEXIN A5

Номер: US20180140668A1
Автор: Camber Ola, Frostegård Johan, Pettersson Knut
Принадлежит:

A method for the prophylaxis or treatment of restenosis comprising administering a therapeutically effective amount of Annexin A5 or a functional analogue or variant thereof to a patient in need of such treatment. A method for the treatment of stenosis in a patient comprising performing an intervention for the treatment of stenosis in conjunction with administering a therapeutically effective amount of Annexin A5 or a functional analogue or variant thereof. A pharmaceutical composition comprising a therapeutically effective amount of Annexin A5 or a functional analogue or variant thereof for the prophylaxis or treatment of restenosis. A drug eluting stent, wherein the drug is Annexin A5 or a functional analogue or variant thereof, and a method of making such a stent. 1. A method of treating or reduction in the development of vascular inflammation in a subject comprising administering to said subject a therapeutically effective amount of Annexin A5 or a functional analog or variant thereof.2. The method of claim 1 , wherein said Annexin A5 or functional analog or variant thereof reduces or prevents of the activation of inflammatory cells in the vascular endothelium.3. The method of claim 1 , wherein said Annexin A5 or functional analog or variant thereof reduces the accumulation of leukocytes in the vascular endothelium.4. The method of claim 1 , wherein the vascular inflammation is provoked by an intervention for the treatment of stenosis.5. The method of claim 4 , wherein the intervention for the treatment of stenosis is a surgical intervention.6. The method of claim 4 , wherein the intervention for the treatment of stenosis is a catheter-based intervention.7. The method of claim 1 , wherein the therapeutically effective amount of Annexin A5 or a functional analogue or variant thereof is administered parenterally claim 1 , intravenously claim 1 , intra-arterially claim 1 , intra-peritoneally claim 1 , intra-muscularly claim 1 , subcutaneously or is administered ...

Подробнее
Номер записи: 74
24-05-2018 дата публикации

DEVICES AND METHODS FOR INHIBITING STENOSIS, OBSTRUCTION, OR CALCIFICATION OF A NATIVE HEART VALVE, STENTED HEART VALVE OR BIOPROSTHESIS

Номер: US20180140747A1
Автор: Rajamannan Nalini M.
Принадлежит: CONCIEVALVE LLC

The present invention relates to methods for inhibiting stenosis, obstruction, or calcification of a valve following implantation of a valve prosthesis or a native valve which develops disease via the Lrp5/Wnt Pathway in the presence of elevated lipids due to elevated Low Density Lipoprotein. This invention involves dispensing a combination of medications to target inflammation and attachment of the target cell and the secondary drugs to inhibit proliferation and calcification on an elastical stent, gortex graft or valve leaflet. The combination therapy inhibits bioprosthesis and native valve calcification with improvement of the longevity of the prosthetic material including the stent, the native valve, and the gortex covering. The valve prosthesis and or gortex graft is mounted on the elastical stent or prosthesis such that the elastical stent is connected to the valve. 1. A method for inhibiting stenosis , obstruction , or calcification of a bioprosthetic valve implanted in a patient comprising:implanting a bioprosthetic valve in a patient to replace a natural heart valve;following implantation administering an effective amount of an anti-hyperlidemic agent in combination with a PCSK9 antibody; andcausing the inhibition of stenosis, obstruction, or calcification of the bioprosthetic valve or natural valve or both.2. The method according to claim 1 , wherein said effective amount of anti-hyperlidemic agents is selected from 10 mg to 80 mg of Atorvastatin claim 1 , 10 mg to 40 mg of Simvastatin claim 1 , 5 mg to 40 mg of Rosuvastatin claim 1 , 20 mg to 80 mg of Pravastatin claim 1 , 1 mg to 4 mg of Pitavastatin and combinations of the foregoing.3. The method of wherein an initial dose of PCSK9 is from 0.25 mg/kg to about 0.5 mg/kg.4. The method of wherein a subsequent dose of PCSK9 is from about 1 mg/kg to about 1.5 mg/kg.5. The method of wherein said initial dose and subsequent dose are separated in time by about one week.6. The method of further comprising ...

Подробнее
Номер записи: 75
04-06-2015 дата публикации

Bioerodible Wraps and Uses There

Номер: US20150150673A1
Автор: David A. Vorp, John J. Stankus, Lorenzo Soletti, Mohammed S. El-Kurdi, William R. Wagner, Yi Hong
Принадлежит: University of Pittsburgh

A tubular tissue graft device is provided comprising a tubular tissue and a restrictive fiber matrix of a bioerodible polymer about a circumference of the tubular tissue. The matrix may be electrospun onto the tubular tissue. In one embodiment, the tubular tissue is from a vein, such as a saphenous vein, useful as an arterial graft, for example and without limitation, in a coronary artery bypass procedure. Also provided is method of preparing a tubular graft comprising depositing a fiber matrix of a bioerodible polymer about a perimeter of a tubular tissue to produce a tubular tissue graft device. A cardiac bypass method comprising bypassing a coronary artery with a tubular tissue graft device comprising a vein and a restrictive fiber matrix of a bioerodible polymer about a circumference of the vein also is provided.

Подробнее
Номер записи: 76
07-05-2020 дата публикации

Gradient Coatings of Biopeptides That Promote Endothelial Cells Selective Adhesion and Directional Migration and Methods of Using the Same

Номер: US20200139010A1
Автор: Gao Changyou, Mao Zhengwei, YU Shan
Принадлежит: Zhejiang University

A two-layer gradient coating article is provided that is operable to cause selective adhesion and directional migration of endothelial cells. The first layer includes cell-resisting polymers that repels cells, the second layer includes one layer of peptides that has affinity to and binds specifically to endothelial cells. Furthermore, the peptides are distributed in a gradient in which attached ECs migrate towards the direction of increased concentration, thus enriching the ECs to a desired locus. The combination of a cell-repelling layer and a graded affinity peptide produces a unique result of selective adhesion, directional migration, thus local enrichment of endothelial cells. A method for using such gradient coating article and its potential use in treating cardiovascular diseases are also provided. The invention provides an inexpensive, stable and effective means for attracting ECs to desirable locations. 1. A gradient coating article configured to induce selective adhesion and directional migration of endothelial cells , comprising:a first layer of cell-resisting polymers that repels cell adhesion nondiscriminatory; anda second layer of peptides having specific affinity to, and operable to interact specifically with, endothelial cells, wherein the peptides are distributed in a concentration gradient configured to induce the endothelial cells to migrate towards the direction of increased peptide concentration at a rate that is higher than smooth muscle cells, and wherein the second layer is covalently linked to the first layer;wherein the first layer of cell-resisting polymers comprises an evenly distributed polymer brushes of single polymer molecular thickness.2. The gradient coating article according to claim 1 , wherein the gradient coating is operable to repel at least 80% of non-endothelial cells and induce the adhesion of substantially all endothelial cells.3. The gradient coating article according to claim 1 , wherein the coating is operable to induce ...

Подробнее
Номер записи: 77
17-06-2021 дата публикации

Prosthetic Venous Valves

Номер: US20210177598A1
Автор: Matheny Robert G.
Принадлежит:

A conical shaped venous valve structure formed from collagenous mammalian tissue. The valve structure includes a plurality of fluid flow modulating means that open and allow antegrade blood to be transmitted out of the valve structure and, into and through an associated cardiovascular vessel, when the valve structure is disposed in the cardiovascular vessel and the antegrade blood exhibits a positive pressure relative to the exterior pressure, whereby a negative hydrostatic pressure gradient is generated or present proximate the flow modulating means and/or a first positive pressure differential between first internal valvular pressure and first external valvular pressure is generated proximate the flow modulating regions, and close and prevent retrograde blood from flowing into the valve structure and, thereby, cardiovascular vessel, when a positive hydrostatic pressure gradient is generated or present proximate the flow modulating means and/or the first positive pressure differential transitions to a second pressure differential between second internal valvular pressure and second external valvular pressure, the second pressure differential being lower than the first positive pressure differential. 1. A prosthetic venous valve for modulating fluid flow through a cardiovascular vessel , comprising:a base valve member comprising crosslinked mammalian collagenous tissue, said crosslinked mammalian collagenous tissue comprising crosslinked pericardium tissue,said crosslinked pericardium tissue comprising an elastic phase slope (E) in the range of 0.3 MPa to 0.5 MPa,said base valve member comprising a taper region, an internal region, an exterior region, an open proximal valve member end and a closed distal valve member end, said open proximal valve member end being configured and adapted to engage said cardiovascular vessel, receive antegrade blood flow therein and direct said antegrade blood flow into said internal region of said base valve member, said open proximal ...

Подробнее
Номер записи: 78
31-05-2018 дата публикации

PRE-STRESSING AND CAPPING BIOPROSTHETIC TISSUE

Номер: US20180147323A1
Автор: Davidson James A., Dobler Darin P., Dove Jeffrey S.
Принадлежит:

A treatment for bioprosthetic tissue used in implants or for assembled bioprosthetic heart valves to reduce in vivo calcification is disclosed. The method includes preconditioning, pre-stressing, or pre-damaging fixed bioprosthetic tissue in a manner that mimics the damage associated with post-implant use, while, and/or subsequently applying a calcification mitigant such as a capping agent or a linking agent to the damaged tissue. The capping agent suppresses the formation of binding sites in the tissue that are exposed or generated by the damage process (service stress) and otherwise would, upon implant, attract calcium, phosphate, immunogenic factors, or other precursors to calcification. The linking agent will act as an elastic reinforcement or shock-absorbing spring element in the tissue structure at the site of damage from the pre-stressing. In one method, tissue leaflets in assembled bioprosthetic heart valves are preconditioned by simulating actual flow conditions for a predetermined number of cycles, during or after which the valve is exposed to the capping agent. 1. A bioprosthetic tissue for implantation in a subject , the bioprosthetic tissue comprising:a cross-linked bioprosthetic tissue comprising localized micro collagen fibril damage at sites of flexion and acid binding sites; andone or more capping agents coupled to the acid binding sites to produce capped acid binding sites;wherein a content of the acid binding sites is at least 10% or greater in the cross-linked bioprosthetic tissue comprising localized micro collagen fibril damage at sites of flexion than in a cross-linked bioprosthetic tissue not having localized micro collagen fibril damage at sites of flexion; andwherein the cross-linked bioprosthetic tissue comprising localized micro collagen fibril damage at sites of flexion and capped acid binding sites has a reduced propensity to calcify in vivo as compared to the cross-linked bioprosthetic tissue not having micro collagen fibril damage at ...

Подробнее
Номер записи: 79
11-06-2015 дата публикации

Method for preparing decellularized tissue product, and graft provided with decellularized tissue product

Номер: US20150157667A1
Автор: Akio Kishida, Jun Negishi, Kuniharu Kobayashi, Seiichi Funamoto, Souichiro Kuwa, Takao Ema, Yoshihide Hashimoto
Принадлежит: Adeka Corp

Provided are: a method for preparing a decellularized tissue product in which decellularized tissue can be filled with liquid while changes in the structure of support tissue constituting the decellularized tissue are inhibited; and a graft provided with a decellularized tissue product. The method for preparing a decellularized tissue product includes a reduced-pressure step for bringing an animal-derived decellularized tissue material and a liquid into contact under reduced-pressure conditions, and/or a pressurized step for bringing same into contact under pressurized conditions. The graft is provided with a decellularized tissue product prepared by the method of preparation.

Подробнее
Номер записи: 80
07-05-2020 дата публикации

SELF-ASSEMBLING MULTICELLULAR BODIES AND METHODS OF PRODUCING A THREE-DIMENSIONAL BIOLOGICAL STRUCTURE USING THE SAME

Номер: US20200140809A1
Автор: FORGACS Gabor, MARGA Francoise Suzanne, NOROTTE Cyrille
Принадлежит:

Structures and methods for tissue engineering include a multicellular body including a plurality of living cells. A plurality of multicellular bodies can be arranged in a pattern and allowed to fuse to form an engineered tissue. The arrangement can include filler bodies including a biocompatible material that resists migration and ingrowth of cells from the multicellular bodies and that is resistant to adherence of cells to it. Three-dimensional constructs can be assembled by printing or otherwise stacking the multicellular bodies and filler bodies such that there is direct contact between adjoining multicellular bodies, suitably along a contact area that has a substantial length. The direct contact between the multicellular bodies promotes efficient and reliable fusion. The increased contact area between adjoining multicellular bodies also promotes efficient and reliable fusion. Methods of producing multicellular bodies having characteristics that facilitate assembly of the three-dimensional constructs are also provided. 1174.-. (canceled)175. A method of producing a multicellular body comprising a plurality of living cells , the method comprising:shaping a cell paste comprising a plurality of living cells in a device that holds the cell paste in a three-dimensional shape; andincubating the shaped cell paste in a controlled environment while it is held in said three-dimensional shape to produce a cohesive body that is capable of supporting itself on a flat surface.176. The method of claim 175 , further comprising producing the cell paste by mixing a plurality of living cells with a tissue culture medium.177. The method of claim 176 , wherein the producing comprises compacting the living cells.178. The method of claim 177 , wherein the compacting comprises centrifuging a cell suspension comprising the plurality of living cells.179. The method of claim 175 , wherein the shaping comprises retaining the cell paste in a first shaping device to allow the cells to ...

Подробнее
Номер записи: 81
01-06-2017 дата публикации

SELF-ASSEMBLING MULTICELLULAR BODIES AND METHODS OF PRODUCING A THREE-DIMENSIONAL BIOLOGICAL STRUCTURE USING THE SAME

Номер: US20170152474A1
Автор: FORGACS Gabor, MARGA Francoise Suzanne, NOROTTE Cyrille
Принадлежит:

Structures and methods for tissue engineering include a multicellular body including a plurality of living cells. A plurality of multicellular bodies can be arranged in a pattern and allowed to fuse to form an engineered tissue. The arrangement can include filler bodies including a biocompatible material that resists migration and ingrowth of cells from the multicellular bodies and that is resistant to adherence of cells to it. Three-dimensional constructs can be assembled by printing or otherwise stacking the multicellular bodies and filler bodies such that there is direct contact between adjoining multicellular bodies, suitably along a contact area that has a substantial length. The direct contact between the multicellular bodies promotes efficient and reliable fusion. The increased contact area between adjoining multicellular bodies also promotes efficient and reliable fusion. Methods of producing multicellular bodies having characteristics that facilitate assembly of the three-dimensional constructs are also provided. 1174-. (canceled)175. A method of producing a multicellular body comprising a plurality of living cells , the method comprising:shaping a cell paste comprising a plurality of living cells in a device that holds the cell paste in a three-dimensional shape; andincubating the shaped cell paste in a controlled environment while it is held in said three-dimensional shape to produce a cohesive body that is capable of supporting itself on a flat surface.176. The method of claim 175 , further comprising producing the cell paste by mixing a plurality of living cells with a tissue culture medium.177. The method of claim 176 , wherein the producing comprises compacting the living cells.178. The method of claim 177 , wherein the compacting comprises centrifuging a cell suspension comprising the plurality of living cells.179. The method of claim 175 , wherein the shaping comprises retaining the cell paste in a first shaping device to allow the cells to ...

Подробнее
Номер записи: 82
07-06-2018 дата публикации

FLOWABLE TISSUE PRODUCTS

Номер: US20180153675A1
Автор: Czeczuga Joshua, Hayzlett Mark, Kabaria Nimesh, Munoz Ivis
Принадлежит: LIFECELL CORPORATION

The present disclosure provides tissue fillers. The tissue fillers can include a plurality of tissue particles formed from acellular tissue matrix fragments. The tissue fillers can be used to fill tissue sites, such as voids formed after tissue resection. 1. A method for producing a tissue composition , comprising:selecting a tissue matrix;treating the tissue matrix to produce fragments having a length between about 5 μm and 300 μm; andforming the fragments into a plurality of particles, each particle having a longest dimension between about 1 mm and about 5 mm.2. The method of claim 1 , further comprising drying the particles.3. The method of claim 2 , wherein drying the particles includes subjecting the particles to a convective drying process.4. The method of claim 1 , further including treating the particles with a dehydrothermal treatment process.5. The method of claim 1 , wherein forming the fragments into a plurality of particles includes compressing groups of the fragments to produce each particle.6. The method of claim 1 , wherein forming the fragments into a plurality of particles includes placing small groups of the fragments in a cold environment to freeze the groups.7. The method of claim 6 , wherein placing small groups of the fragments in a cold environment to freeze the groups includes extruding the small groups into a cryogenic liquid.8. The method of claim 1 , wherein the plurality of particles includes substantially spherical particles.9. The method of claim 1 , wherein treating the tissue matrix to produce fragments includes milling the tissue matrix.10. The method of claim 1 , wherein the fragments are strands of tissue matrix.11. The method of claim 1 , wherein the tissue matrix is dermal tissue matrix.12. The method of claim 1 , wherein the tissue matrix is porcine tissue matrix.13. The method of claim 1 , wherein the particles are flowable.14. The method of claim 1 , wherein the tissue matrix is an acellular tissue matrix.15. A tissue product ...

Подробнее
Номер записи: 83
22-09-2022 дата публикации

QUILTED IMPLANTABLE GRAFT

Номер: US20220296351A1
Автор: Bleyer Mark W., Fearnot Neal E., Miller Jeffrey, Patel Umesh H.
Принадлежит: Cook Biotech Incorporated

Described are embodiments of a multilaminate or multiple layer implantable surgical graft with an illustrative graft comprising a remodelable collagenous sheet material, the graft including one or more interweaving members to stitch together the graft to help prevent the layers from delaminating or separating during handling and the initial stages of remodeling. The interweaving members may comprise lines of suture, thread, individual stitches, strips of material, etc. that are woven through the layers of biomaterial in a desired pattern. In one embodiment, the interweaving members comprise a pharmacologically active substance, such as a drug, growth factors, etc. to elicit a desired biological response in the host tissue. In another embodiment, the graft further comprises a reinforcing material, such as a synthetic mesh, within the layers of remodelable biomaterial and stitched together by one or more interweaving members. 1. A multilayer surgical graft , comprising:a first remodelable extracellular matrix sheet;a second remodelable extracellular matrix sheet;a synthetic mesh material disposed between said first remodelable extracellular matrix sheet and said second remodelable extracellular matrix sheet; andat least one interweaving member interwoven through said first remodelable extracellular matrix sheet and said second remodelable extracellular matrix sheet such that said first remodelable extracellular matrix sheet and said second remodelable extracellular matrix sheet are affixed together.2. The multilayer surgical graft of claim 1 , wherein said first remodelable extracellular matrix sheet includes two or more laminated remodelable extracellular matrix layers.3. The multilayer surgical graft of claim 2 , wherein said second remodelable extracellular matrix sheet includes two or more laminated remodelable extracellular matrix layers.4. The multilayer surgical graft of claim 3 , wherein said at least one interweaving member comprises a bioresorbable material. ...

Подробнее
Номер записи: 84
23-05-2019 дата публикации

HEART VALVE WITH REDUCED CALCIFICATION

Номер: US20190151083A1
Автор: Davidson James A., Dobler Darin P., Dove Jeffrey S., Wright Gregory A.
Принадлежит:

A method for manufacturing a heart valve using bioprosthetic tissue that exhibits reduced in vivo calcification. The method includes applying a calcification mitigant such as a capping agent or an antioxidant to the tissue to specifically inhibit oxidation in tissue. Also, the method can be used to inhibit oxidation in dehydrated tissue. The capping agent suppresses the formation of binding sites in the tissue that are exposed or generated by the oxidation and otherwise would, upon implant, attract calcium, phosphate, immunogenic factors, or other precursors to calcification. In one method, tissue leaflets in assembled bioprosthetic heart valves are pretreated with an aldehyde capping agent prior to dehydration and sterilization. 1. A method for manufacturing a heart valve , the method comprising:exposing a heart valve to a solution comprising a capping agent;treating the heart valve with a glycerol treatment solution;packaging the heart valve; andsterilizing the packaged heart valve.2. The method of claim 1 , wherein the heart valve is crosslinked before the exposing.3. The method of claim 2 , wherein the heart valve is crosslinked with an aldehyde.4. The method of claim 3 , wherein the aldehyde is glutaraldehyde.5. The method of claim 1 , wherein:the heart valve comprises functional groups comprising one or both of aldehyde groups and carboxylic acid groups; andthe exposing at least partially blocks, removes or alters the functional groups.6. The method of claim 1 , wherein the capping agent comprises any one or a combination of: an amine claim 1 , an amino acid claim 1 , an amino sulfonate claim 1 , a hydrophilic multifunctional polymer claim 1 , a hydrophobic multifunction polymer claim 1 , an alpha-dicarbonyl claim 1 , a hydrazide claim 1 , an N claim 1 ,N-disuccinimidyl carbonate claim 1 , a carbodiimide claim 1 , a 2-chloro-1-methylpyridium iodide claim 1 , an antibiotic claim 1 , a cell recruiting agent claim 1 , a heparin claim 1 , a mono-alkane claim 1 , a ...

Подробнее
Номер записи: 85
22-09-2022 дата публикации

HYBRID ANNULOPLASTY RING FOR TRICUSPID OR MITRAL VALVE REPAIR

Номер: US20220296775A1
Автор: De La Fuente Angela B., Do Vicky Hong, Gui Liqiong, Han Jingjia, Hoang Lien Huong Thi, Miraki Manouchehr A., SHANG Hao, Tian Bin
Принадлежит:

An annuloplasty ring prosthesis comprising a frame having an outer surface; and a cover surrounding the frame. The cover comprises a bioprosthetic tissue that can be regenerative or fixed and non-regenerative. The frame can be bioabsorbable or non-degradable. A ring prosthesis and a method of manufacturing a ring prosthesis is also provided. The ring prosthesis comprising an elongated rod member formed into a substantially ring shape, the elongated rod member being formed substantially from a flat bioprosthetic tissue. 1. An annuloplasty ring prosthesis comprising:a frame comprising an outer surface; anda cover surrounding the outer surface of the frame;wherein the cover comprises a bioprosthetic tissue.2. The annuloplasty ring prosthesis of claim 1 , wherein the bioprosthetic tissue is a fixed claim 1 , non-regenerative bioprosthetic tissue.3. The annuloplasty ring prosthesis of claim 2 , wherein the fixed claim 2 , non-regenerative bioprosthetic tissue is selected from the group consisting of: pericardium claim 2 , blood vessels claim 2 , skin claim 2 , dura mater claim 2 , small intestinal submucosa claim 2 , ligaments claim 2 , tendons claim 2 , muscle claim 2 , ureter claim 2 , urinary bladder claim 2 , liver claim 2 , and heart.4. The annuloplasty ring prosthesis of claim 3 , wherein the fixed claim 3 , non-regenerative bioprosthetic tissue is a pericardium.5. The annuloplasty ring prosthesis of claim 2 , wherein the fixed claim 2 , non-regenerative bioprosthetic tissue is fixed with an aldehyde.6. The annuloplasty ring prosthesis of claim 5 , wherein the aldehyde is a glutaraldehyde.7. The annuloplasty ring prosthesis of claim 5 , wherein free aldehyde groups in the fixed claim 5 , non-regenerative bioprosthetic tissue are subjected to a capping treatment comprising a capping agent.8. The annuloplasty ring prosthesis of claim 7 , wherein the capping agent comprises an amine.9. The annuloplasty ring prosthesis of claim 8 , wherein the capping treatment further ...

Подробнее
Номер записи: 86
22-09-2022 дата публикации

ALLOGENEIC MICROVASCULAR TISSUE FOR SOFT TISSUE TREATMENTS

Номер: US20220296778A1
Автор: EMMITT Richard B., Peterson Dale R.
Принадлежит:

Disclosed are products and methods for treating soft tissue injuries. The provided methods include the production of processed or cryopreserved microvascular tissue. Also provided are products and methods of using processed or cryopreserved microvascular tissue for the treatment of soft tissue injuries. 118-. (canceled)19. A composition comprising a plurality of nonviable progenitor cells with tissue healing activity.20. The composition of claim 19 , wherein less than 50% of the progenitor cells are viable.21. The composition of claim 19 , wherein less than 30% of the progenitor cells are viable.22. The composition of claim 19 , wherein less than 10% of the progenitor cells are viable.23. The composition of claim 19 , wherein the progenitor cells are isolated from microvascular tissue.24. The composition as in one of the - claim 19 , wherein the progenitor cells have been dried.25. The composition as in one of the - claim 19 , wherein the progenitor cells have been cryopreserved.26. The composition as in one of the - claim 19 , wherein the progenitor cells have been lyophilized.27. The composition of claim 19 , wherein some of the progenitor cells have intact cell membranes.28. The composition of claim 19 , wherein the tissue healing activity includes both hard and soft tissues.29. The composition of claim 28 , wherein the tissue healing activity includes healing of bone claim 28 , tendon claim 28 , ligament and skin defects or disorders. This application claims priority to Provisional Application No. 61/454,367, filed Mar. 18, 2011, which is herein incorporated by reference in its entirety.This application is directed to compositions and methods relating to tissue repair using allogeneic microvascular tissue or cells.Tendon injuries are very common. Sprains will heal spontaneously, but complete tears will often lead to disability if not surgically treated. Despite surgical repairs, about 15% of Achilles tendons and 40% of two tendon rotator cuff repairs ...

Подробнее
Номер записи: 87
18-06-2015 дата публикации

DEVICE, SYSTEM, AND METHOD FOR TRANSCATHETER TREATMENT OF VALVE REGURGITATION

Номер: US20150164637A1
Автор: Khairkhahan Alex, Lesh Michael D.
Принадлежит:

The invention relates to a device for use in the transcatheter treatment of mitral valve regurgitation, specifically a coaptation enhancement element for implantation across the valve; a system including the coaptation enhancement element and anchors for implantation; a system including the coaptation enhancement element, catheter and driver; and a method for transcatheter implantation of a coaptation element across a heart valve.

Подробнее
Номер записи: 88
14-05-2020 дата публикации

DETECTION OF BIOPROSTHETIC VALVE DEGENERATION

Номер: US20200147264A1
Автор: Chocron Richard, GENDRON Nicolas, SMADJA David
Принадлежит:

The invention relates to a method for predicting or diagnosing a risk of bioprosthetic valve degeneration. Further, the invention relates to a medical device, in particular a bioprosthetic valve coated with EPCR less prone to degeneration and/or calcification once implanted. 1. A method for diagnosing or monitoring a risk of bioprosthetic valve degeneration in a subject , said method comprising the following steps :i) measuring sEPCR level or amount in a biological sample previously collected from said subject, andii) comparing said level or amount to a reference, wherein diagnostic or monitoring is based on the result of the comparing step.2. The method for diagnosing or monitoring according to claim 1 , wherein measuring sEPCR level or amount according to step i) comprises contacting said sample with a sEPCR binding partner.3. The method for diagnosing or monitoring according to claim 1 , wherein said method further comprises a pretreatment step of said sample before step i).4. The method for diagnosing or monitoring according to claim 3 , wherein said pretreatment step comprises a transformation of sEPCR for measuring the level or amount of sEPCR.5. The method for diagnosing or monitoring according to claim 4 , wherein the step i) comprises contacting the transformed sEPCR with a binding partner capable of selectively interacting with said transformed sEPCR.6. The method for diagnosing or monitoring according to claim 1 , wherein when the level of sEPCR is lower than 130 ng/mL claim 1 , preferably 110 ng claim 1 , then the subject is diagnosed as suffering or at risk of suffering from bioprosthetic valve degeneration.7. The method for diagnosing or monitoring according to claim 1 , wherein the level of sEPCR is lower than 108 ng/mL claim 1 , then the subject is diagnosed as suffering or at risk of suffering from bioprosthetic valve degeneration.8. The method for diagnosing or monitoring according to claim 1 , wherein the sample is selected from whole blood claim ...

Подробнее
Номер записи: 89
14-05-2020 дата публикации

BIOENGINEERED ALLOGENEIC BLOOD VESSEL

Номер: US20200147272A1
Автор: Olausson Michael, Sumitran-Holgersson Suchitra
Принадлежит: VeriGraft AB

The present invention relates to methods for recellurization of blood vessels. This method is particularly useful for producing an allogeneic vein, wherein a donor vein is decellularized and then recellularized using whole blood or bone marrow stem cells. The allogeneic veins produced by the methods disclosed herein are particularly advantageous for implantation or transplantation into patients with vascular diseases. 131.-. (canceled)32. A method of decellularizing a blood vessel comprising treating the blood vessel to be decellularized with a first solution comprising Triton X 100 , followed by treating the blood vessel to be decellularized with a second solution comprising tri-n-butyl phosphate.33. The method of claim 32 , wherein one or more of the solutions further comprises a DNase.34. The method of claim 33 , wherein the DNase is DNase I.35. The method of claim 32 , wherein the treatment is performed at least twice with a washing step in between treatment with each solution.36. The method of claim 35 , wherein the washing is performed with PBS.37. The method of claim 32 , wherein the blood vessel is a vein or an artery.38. The method of claim 32 , wherein the first solution comprises 1% Triton X 100 and the second solution comprises 1% tri-n-butyl phosphate.39. The method of claim 32 , wherein claim 32 , following the treatment claim 32 , the decellularized blood vessel is free of cell nuclei and HLA class I and II antigens.40. A decellularized blood vessel produced by the method of . This application is a continuation of U.S. application Ser. No. 15/169,868, filed on Jun. 1, 2016, which is a continuation of U.S. application Ser. No. 14/723,727, filed May 28, 2015 (now U.S. Pat. No. 9,433,706), which is a continuation of U.S. application Ser. No. 14/364,756, filed Jun. 12, 2014 (now U.S. Pat. No. 9,090,879), which is a national stage application, filed under 35 U.S.C. § 371, of International Application No. PCT/IB2013/000873, filed Mar. 1, 2013, which claims ...

Подробнее
Номер записи: 90
14-06-2018 дата публикации

COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING TISSUE INJURY AND DISEASE

Номер: US20180161379A1
Автор: EL-KALAY Mohammad A., Gong Glen, MATTERN Ralph-Heiko, Ohashi Kevin L., Peterson Dale R., PICKETT Lael J., WILSON Corey
Принадлежит:

The present invention provides novel compositions comprising multipotent cells or microvascular tissue, wherein the cells or tissue has been sterilized and/or treated to inactivated viruses, and related methods of using these compositions to treat or prevent tissue injury or disease in an allogeneic subject. 1. A method for the treatment of damaged nerves comprising delivery of a therapeutic agent to a subject in need thereof wherein the therapeutic agent comprises enriched , nonviable multipotent cells.2. The method of wherein the multipotent cells are sterilized by irradiation.3. The method of wherein the multipotent cells have been isolated from microvascular tissue.4. The method of wherein the multipotent cells have been enriched by a method selected from the group consisting of removal of extraneous tissue and culturing the multipotent cells.5. The method of wherein the multipotent cells have been enriched by culturing the multipotent cells.6. The method of wherein delivery of a therapeutic agent comprises injection or surgical application to the region of damaged nerves.7. The method of wherein delivery of a therapeutic agent comprises systemic injection.8. The method of wherein the therapeutic agent is a powder claim 1 , gel or ointment applied topically near the site of nerve damage.9. A wound healing composition comprising sterilized microvascular tissue formulated for topical administration claim 1 , wherein the microvascular tissue comprises multipotent cells claim 1 , has angiogenic or anti-inflammatory activity greater than saline alone claim 1 , and wherein less than or equal to 50% of the multipotent cells are viable.10. The composition of wherein the microvascular tissue is sterilized by irradiation.11. The composition of wherein the microvascular tissue comprises enriched multipotent cells.12. The composition of wherein the microvascular tissue is enriched by a method selected from the group consisting of removal of extraneous tissue or culturing ...

Подробнее
Номер записи: 91
29-09-2022 дата публикации

Prosthetic Valves and Related Inventions

Номер: US20220304802A1
Автор: Georg Lutter, Kemal Schankereli, Lucian Lozonschi, Robert Vidlund
Принадлежит: Tendyne Holdings Inc

This invention relates to the design and function of a compressible valve replacement prosthesis, collared or uncollared, which can be deployed into a beating heart without extracorporeal circulation using a transcatheter delivery system. The design as discussed focuses on the deployment of a device via a minimally invasive fashion and by way of example considers a minimally invasive surgical procedure preferably utilizing the intercostal or subxyphoid space for valve introduction. In order to accomplish this, the valve is formed in such a manner that it can be compressed to fit within a delivery system and secondarily ejected from the delivery system into the annulus of a target valve such as a mitral valve or tricuspid valve.

Подробнее
Номер записи: 92
01-07-2021 дата публикации

PROSTHETIC HEART VALVE ASSEMBLY

Номер: US20210196457A1
Автор: Chau Mark, Nguyen Son V., Rowe Stanton J.
Принадлежит: EDWARDS LIFESCIENCES CORPORATION

A prosthetic heart valve assembly includes a self-expandable stent having an inlet end and an outlet end and a passageway extending therethrough. The stent includes a plurality of rows of prongs on the outer surface of the stent. A valve portion comprising a plurality of leaflets is positioned within the passageway for permitting blood to flow through the passageway from the inlet end to the outlet end while blocking flow in the opposite direction. The stent further includes a flared upper portion shaped for placement along a supra-annular surface of an annulus for preventing downward migration of the prosthetic valve assembly into a ventricle. Each of the prongs has a tip pointing toward the inlet end for penetrating surrounding tissue and preventing upward migration of the prosthetic heart valve assembly toward an atrium. 1. A prosthetic heart valve assembly comprising:a radially self-expandable stent made from a shape memory material, wherein the stent comprises a flared upper portion defining an inlet end of the stent, a lower portion defining an outlet end of the stent, and an intermediate portion between the upper and lower portions, the stent having a passageway extending therethrough, wherein an entire extent of the stent downstream of the inlet end has a smaller diameter than a diameter of the inlet end, the stent further comprising a plurality of prongs disposed along an outer surface thereof;wherein the prongs are arranged in a plurality of rows of prongs, each row comprising a plurality of prongs that are circumferentially spaced from each other, wherein the rows are spaced from each other in a direction extending along a length of the stent and wherein all of the prongs have tips pointing toward the inlet end; anda valve portion positioned in the passageway, wherein the valve portion comprises a plurality of leaflets that permit the flow of the blood through the prosthetic heart valve assembly in a direction from the inlet end to the outlet end and ...

Подробнее
Номер записи: 93
01-07-2021 дата публикации

Heart valve replacement prosthesis with advantageous sealing and loading properties

Номер: US20210196459A1
Автор: Coralie Marchand, Helmut Straubinger, Luis Gerardo HURTADO AGUILAR
Принадлежит: Tricares SAS

The invention relates to a replacement heart valve prosthesis with advantageous sealing properties and advantageous properties for loading into a delivery system, e.g. a catheter.

Подробнее
Номер записи: 94
22-06-2017 дата публикации

METHODS FOR PREPARING DRY CROSS-LINKED TISSUE

Номер: US20170173214A1
Автор: Garde Kshitija, Guo Ya, McKinley Laura, Tien Tracey, Wang Wei, Wong Benjamin
Принадлежит:

A method of preparing dry cross-linked biological tissue. A processing solution is prepared that contains a cross-linking agent and an organic water-soluble liquid. Biological tissue is immersed in the processing solution for an effective period of time to substantially displace water from the biological tissue and substantially cross-link the biological tissue to form dry cross-linked biological tissue. 1. A method of preparing dry cross-linked biological tissue comprising:preparing a processing solution that comprises a cross-linking agent and an organic water-soluble liquid; andimmersing a biological tissue in the processing solution for an effective period of time to substantially displace water from the biological tissue and substantially cross-link the biological tissue to form dry cross-linked biological tissue.2. The method of claim 1 , wherein the cross-linking agent is provided in the processing solution at a concentration of between about 0.10 percent by weight and about 1.00 percent by weight.3. The method of claim 1 , wherein the cross-linking agent comprises at least one of an amine- and a carboxyl-reactive crosslinker.4. The method of claim 1 , wherein the cross-linking agent includes glutaraldehyde.51070. The method of claim 1 , wherein the organic water-soluble liquid is provided in the processing solution at a concentration of between about percent by volume and about percent by volume.6. The method of claim 1 , wherein the organic water-soluble liquid comprises at least one polyhydric alcohol.7. The method of claim 1 , wherein the organic water-soluble liquid includes at least one of glycerol claim 1 , sucrose claim 1 , propylene glycol claim 1 , triethylene glycol claim 1 , and tetraethylene glycol.8. The method of claim 1 , wherein the processing solution is saline buffered.9. The method of claim 1 , wherein the biological tissue is fresh prior to being immersed in the processing solution.10. The method of claim 1 , wherein the effective period ...

Подробнее
Номер записи: 95
28-05-2020 дата публикации

METHODS OF PRODUCING MULTI-LAYERED TUBULAR TISSUE CONSTRUCTS

Номер: US20200164109A1
Автор: Homan Kimberly A., Kolesky David B., Kroll Katharina Theresa, Lewis Jennifer A., Lustenberger Patrick, Skylar-Scott Mark A., Uzel Sebastien G.M.
Принадлежит: President and Fellows of Harvard College

Described are methods for producing multi-layered tubular tissue structures, tissue structures produced by the methods, and their use. 1. A method of producing a perfusable multi-layered tubular tissue construct , comprising: a plurality of concentric and coaxial cell-laden ink layers, each cell-laden ink layer comprising one or more predetermined cell types and extending at least a portion of the length of the filament, wherein the one or more predetermined cell types are cell aggregates or clusters of cells, and', 'a core comprising a fugitive ink, wherein the fugitive ink serves as a template for an open perfusable lumen within the filament;, 'depositing on a substrate one or more filaments, each filament comprisingremoving the fugitive ink to create the open perfusable lumen; andexposing the one or more filaments to fluid perfusion to induce cell proliferation and development, thereby producing the perfusable multi-layered tubular tissue construct.2. The method of claim 1 , wherein the step of depositing on a substrate one or more filaments comprises:flowing the fugitive ink through a first extrusion tube;flowing a first cell-laden ink comprising one or more predetermined cell types through a second extrusion tube overlaying the first extrusion tube, the first cell-laden ink flowing around and enclosing the fugitive ink;flowing a second cell-laden ink comprising one or more predetermined cell types through a third extrusion tube overlaying the second extrusion tube, the second cell-laden ink flowing around and enclosing the first cell-laden ink,thereby forming the core comprising the fugitive ink surrounded by an inner layer comprising a first cell-laden ink layer and an outer layer comprising a second cell-laden ink layer.3. The method of claim 2 , further comprising providing an extrusion head including the first claim 2 , second claim 2 , and third extrusion tubes arranged in a concentric configuration claim 2 , wherein the extrusion head is moved relative to ...

Подробнее
Номер записи: 96
08-07-2021 дата публикации

ACELLULAR ORGANS, AND METHODS OF PRODUCING THE SAME

Номер: US20210205497A1
Автор: CHAO Chao-Chin, HSIEH Dar-Jen, KUO Jer-Cheng, LAI Yi-Ping, PERIASAMY Srinivasan, Wei Chao-Yi
Принадлежит: Acro Biomedical Company. Ltd.

Provided are methods of producing an acellular organ. The method includes the steps of, subjecting an organ derived from an animal to a static supercritical fluid (SCF) treatment followed by a dynamic SCF treatment. Optionally, the method of the present disclosure further includes a hypertonic and a hypotonic treatments prior to the static SCF treatment, and/or a neutralizing treatment after the dynamic SCF treatment. Also disclosed herein are acellular organs produced by the present method. 1. A method of producing an acellular organ , comprising:(a) subjecting an organ to a first supercritical fluid (SCF) in the presence of a first co-solvent under a first pressure of 200-500 bar at a first temperature between 30-50° C. for a first period of 10-100 minutes; and(b) subjecting the first SCF treated organ of the step (a) with a continuous flow of a second SCF in the presence of a second co-solvent under a second pressure of 200-500 bar at a second temperature between 30-50° C. for a second period of 10-100 minutes, wherein the flow rate of the second SCF is 10-30 liter per minute;wherein, the method does not comprise the step of treating the organ with an agent selected from the group consisting of an enzyme, an ion chelating agent, a detergent, a glycerol, and a combination thereof.2. The method of claim 1 , wherein the first and second SCFs are independently selected from the group consisting of supercritical carbon dioxide (ScCO) claim 1 , supercritical nitrous oxide (ScNO) claim 1 , supercritical alkane claim 1 , supercritical alkene claim 1 , supercritical alcohol claim 1 , supercritical acetone claim 1 , and a combination thereof.3. The method of claim 2 , wherein each of the first and second SCFs is the ScCO.4. The method of claim 3 , whereineach of the first and second pressures is 350 bar;each of the first and second temperatures is 40° C.;each of the first and second periods is 10-80 minutes; andthe flow rate of the second SCF is 20 liter per minute.5. The ...

Подробнее
Номер записи: 97
08-07-2021 дата публикации

VESSEL COMPRESSION WITH HEMODYNAMIC WAVE REFLECTION TO CONTROL VASCULAR WAVE DYNAMICS AND ENHANCE BLOOD FLOW

Номер: US20210205598A1
Автор: Csete Marie, Gharib Morteza, Pahlevan Niema M.
Принадлежит:

A system configured to be at least partially implanted along an aorta includes an inelastic, static member and a pinching member. The pinching member is configured to receive an activation signal at an activation rate and in response to the activation signal, repeatedly compress the aorta at the second location at the activation rate to pump fluid within the aorta in a desired pumping direction. The system is configured to selectively control wave reflections in order to achieve both improved wave dynamics to reduce cardiac load and increased (or at least non-diminished) blood flow to targeted organs within the cardiovascular system. 1. A system configured to be at least partially implanted in mammal along an aorta , the system comprising:an inelastic member comprising a biocompatible material, the inelastic member configured to surround at least a portion of an outer surface of an aorta at a first location along the aorta; anda pinching member comprising a second biocompatible material, the pinching member configured to surround at least a second portion the outer surface of the aorta at a second location along the aorta,wherein the pinching member is further configured to receive an activation signal at an activation rate and in response to the activation signal, repeatedly compress the aorta at the second location at the activation rate to pump fluid within the aorta in a desired pumping direction.2. The system of claim 1 , wherein the pinching member comprises one or more of: a synthetic biocompatible material claim 1 , living cells claim 1 , a tissue-derived matrix or a hydrogel.3. The system of claim 2 , wherein the pinching member comprises cardiomyocytes.4. The system of claim 1 , further comprising an actuator configured to activate the pinching member to compress the aorta in response to the activation signal.5. The system of claim 4 , wherein the pinching member comprises first and second arms claim 4 , and wherein the actuator is configured to cause a ...

Подробнее
Номер записи: 98
13-06-2019 дата публикации

IMPLANT, PREFERABLY FOR THE TREATMENT OF AN ACETABULAR DEFECT

Номер: US20190175793A1
Автор: Koenig Silke
Принадлежит: Aesculap AG

An implant, preferably for treating and/or reconstructing, in particular lining and/or sealing and/or relining and/or at least partially filling an acetabular defect, having at least one flat structure which contains a material that is at least partially decomposable or resorbable in vivo. The invention further relates to a surgical kit and the use of an unfinished flat structure for producing an implant. 122.-. (canceled)23. An implant for use in treating , in particular lining and/or sealing and/or relining and/or at least partially filling an acetabular defect , having at least one flat structure which contains a material that is at least partially decomposable or resorbable in vivo.24. The implant of claim 23 , characterized in that the material has a randomized fiber structure claim 23 , in particular a web or nonwoven fabric structure.25. The implant of claim 23 , characterized in that the material is free of non-collagenous components claim 23 , in particular free of non-collagenous proteins.26. The implant of claim 23 , characterized in that the material is a protein claim 23 , preferably extracellular protein.27. The implant of claim 26 , characterized in that the protein is selected from the group composed of collagen claim 26 , gelatin claim 26 , elastin claim 26 , reticulin claim 26 , fibrin claim 26 , fibronectin claim 26 , laminin claim 26 , albumin and mixtures of at least two of the aforementioned proteins.28. The implant of claim 26 , characterized in that the protein is collagen claim 26 , in particular collagen type I claim 26 , collagen type III or a mixture of collagen type I and collagen type III.29. The implant of claim 23 , characterized in that the material is a xenogeneic claim 23 , in particular bovine claim 23 , tissue.30. The implant of claim 29 , characterized in that the tissue is pericardium claim 29 , in particular bovine pericardium.31. The implant of claim 23 , characterized in that the material is a synthetic polymer selected in ...

Подробнее
Номер записи: 99
04-06-2020 дата публикации

Method for genetically modifying a vascularised tissue

Номер: US20200170243A1
Автор: Constanca Ferreira de Figueiredo, Rainer Blasczyk
Принадлежит: MEDIZINISCHE HOCHSCHULE HANNOVER

The invention provides an ex-vivo method, i.e. an in vitro method, for genetically modifying cells of a vascularised tissue, which can be anorgan, during normothermic or subnormothermic perfusion without damaging the tissue or its cells due to oxygen undersupply. The method enables keeping the vascularised tissue at normothermic or subnormothermic conditions over a sufficient period of time to genetically modify the cells e.g. with viral vectors.

Подробнее
Номер записи: 100